<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">32303592</PMID>        <DateCompleted>            <Year>2020</Year>            <Month>06</Month>            <Day>30</Day>        </DateCompleted>        <DateRevised>            <Year>2020</Year>            <Month>12</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Electronic-Print">            <Journal>                <ISSN IssnType="Electronic">1098-5514</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>94</Volume>                    <Issue>13</Issue>                    <PubDate>                        <Year>2020</Year>                        <Month>06</Month>                        <Day>16</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of virology</Title>                <ISOAbbreviation>J Virol</ISOAbbreviation>            </Journal>            <ArticleTitle>Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">e00510-20</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00510-20</ELocationID>            <Abstract>                <AbstractText>Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen A [HLA-A], -B, and -C genes) may affect susceptibility to and severity of the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We performed a comprehensive <i>in silico</i> analysis of viral peptide-MHC class I binding affinity across 145 HLA-A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explored the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome was successfully sampled and was represented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting that individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (M. Lin, H.-T. Tseng, J. A. Trejaut, H.-L. Lee, et al., BMC Med Genet 4:9, 2003, https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-4-9). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting that it could enable cross-protective T-cell-based immunity. Finally, we reported global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.<b>IMPORTANCE</b> Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of severity of viral disease in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2020 Nguyen et al.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nguyen</LastName>                    <ForeName>Austin</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">0000-0001-7940-4830</Identifier>                    <AffiliationInfo>                        <Affiliation>Computational Biology Program, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>David</LastName>                    <ForeName>Julianne K</ForeName>                    <Initials>JK</Initials>                    <Identifier Source="ORCID">0000-0003-2690-8239</Identifier>                    <AffiliationInfo>                        <Affiliation>Computational Biology Program, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maden</LastName>                    <ForeName>Sean K</ForeName>                    <Initials>SK</Initials>                    <Identifier Source="ORCID">0000-0002-2212-4894</Identifier>                    <AffiliationInfo>                        <Affiliation>Computational Biology Program, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wood</LastName>                    <ForeName>Mary A</ForeName>                    <Initials>MA</Initials>                    <Identifier Source="ORCID">0000-0003-4011-3811</Identifier>                    <AffiliationInfo>                        <Affiliation>Computational Biology Program, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Portland VA Research Foundation, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Weeder</LastName>                    <ForeName>Benjamin R</ForeName>                    <Initials>BR</Initials>                    <Identifier Source="ORCID">0000-0002-4128-5861</Identifier>                    <AffiliationInfo>                        <Affiliation>Computational Biology Program, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nellore</LastName>                    <ForeName>Abhinav</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">0000-0001-8145-1484</Identifier>                    <AffiliationInfo>                        <Affiliation>Computational Biology Program, Oregon Health &amp; Science University, Portland, Oregon, USA nellore@ohsu.edu thompsre@ohsu.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thompson</LastName>                    <ForeName>Reid F</ForeName>                    <Initials>RF</Initials>                    <Identifier Source="ORCID">0000-0003-3661-5296</Identifier>                    <AffiliationInfo>                        <Affiliation>Computational Biology Program, Oregon Health &amp; Science University, Portland, Oregon, USA nellore@ohsu.edu thompsre@ohsu.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Medicine, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Hospital and Specialty Medicine, VA Portland Healthcare System, Portland, Oregon, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>IK2 CX002049</GrantID>                    <Acronym>CX</Acronym>                    <Agency>CSRD VA</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013486">Research Support, U.S. Govt, Non-P.H.S.</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2020</Year>                <Month>06</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Virol</MedlineTA>            <NlmUniqueID>0113724</NlmUniqueID>            <ISSNLinking>0022-538X</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="CommentIn">                <RefSource>Front Immunol. 2020 May 28;11:1208</RefSource>                <PMID Version="1">32574270</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019411" MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">COVID-19</Keyword>            <Keyword MajorTopicYN="Y">HLA</Keyword>            <Keyword MajorTopicYN="Y">MHC class I</Keyword>            <Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>            <Keyword MajorTopicYN="Y">coronavirus</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2020</Year>                <Month>03</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2020</Year>                <Month>04</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2020</Year>                <Month>4</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2020</Year>                <Month>7</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2020</Year>                <Month>4</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">32303592</ArticleId>            <ArticleId IdType="pii">JVI.00510-20</ArticleId>            <ArticleId IdType="doi">10.1128/JVI.00510-20</ArticleId>            <ArticleId IdType="pmc">PMC7307149</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32217835</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32007145</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Med Virol. 2020 May;92(5):522-528</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32027036</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Saudi Med J. 2015 Apr;36(4):484-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25828287</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immune Netw. 2016 Oct;16(5):261-270</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27799871</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>mBio. 2020 May 29;11(3):</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32471829</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cancer Immunol Res. 2020 Mar;8(3):396-408</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">31871119</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23580623</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Med Genet. 2003 Sep 12;4:9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12969506</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Mol Syst Biol. 2011 Oct 11;7:539</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21988835</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Med. 2020 Apr;26(4):453-455</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32284614</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">31978945</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunogenetics. 2005 Apr;57(1-2):33-41</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15744535</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 2009 Mar 12;458(7235):211-4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19182777</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32171076</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Clin Infect Dis. 2020 Mar 04;:</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32129843</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Microbes Infect. 2020 Mar;22(2):72-73</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32092539</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet Infect Dis. 2020 Apr 27;:</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32353347</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Viruses. 2020 Feb 25;12(3):</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32106567</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell Rep. 2020 Jun 2;31(9):107725</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32426212</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2020 May 8;368(6491):630-633</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32245784</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Pathogens. 2020 Mar 04;9(3):</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32143502</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2020 Apr 23;382(17):1663-1665</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32187458</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Med. 2005 Apr;11(4 Suppl):S54-62</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15812491</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Autoimmun. 2017 Sep;83:12-21</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28479213</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dis. 2000 May;181(5):1581-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10823757</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S207-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15577575</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>World J Clin Pediatr. 2016 Nov 8;5(4):391-396</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27872828</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Emerg Infect Dis. 2004 Feb;10(2):235-43</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15030689</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Cancer. 2018 Apr 13;18(1):414</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29653567</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Virology. 2005 Feb 20;332(2):498-510</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15680415</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25414323</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>JAMA. 2020 Feb 7;:</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32031570</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32183941</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Bioinformatics. 2009 May 1;25(9):1189-91</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19151095</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">30357391</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32064853</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Autoimmun. 2020 May;109:102434</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32143990</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Rev Immunol. 2011 Jul 15;11(8):532-43</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21760609</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Comput Biol Med. 2020 Apr;119:103670</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32209231</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2017 Nov 1;199(9):3360-3368</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28978689</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hum Vaccin Immunother. 2020 Jun 2;16(6):1232-1238</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32186952</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 2018 Jul 26;174(3):672-687.e27</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">30053426</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Formos Med Assoc. 2020 Mar;119(3):670-673</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32139299</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2002 Dec 15;169(12):6779-86</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12471109</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Eur Respir J. 2020 May 14;55(5):</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32217650</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Tissue Antigens. 2002 Oct;60(4):309-18</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12472660</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 1998 Jul 30;394(6692):482-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9697771</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell Syst. 2018 Jul 25;7(1):129-132.e4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29960884</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Med Virol. 2020 May;92(5):495-500</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32022276</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Biomed Res Int. 2020 May 11;2020:2683286</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32461973</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Front Immunol. 2019 Mar 04;10:349</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">30886616</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32142651</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26553804</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunity. 2020 Jun 16;52(6):971-977.e3</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32413330</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Vaccine. 2009 Dec 30;27 Suppl 6:G21-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20006135</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Med Virol. 2020 Apr;92(4):424-432</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">31981224</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32105090</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32105632</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">32828069</PMID>        <DateCompleted>            <Year>2020</Year>            <Month>09</Month>            <Day>24</Day>        </DateCompleted>        <DateRevised>            <Year>2020</Year>            <Month>12</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-0534</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>124</Volume>                    <PubDate>                        <Year>2020</Year>                        <Month>09</Month>                    </PubDate>                </JournalIssue>                <Title>Computers in biology and medicine</Title>                <ISOAbbreviation>Comput Biol Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.</ArticleTitle>            <Pagination>                <MedlinePgn>103967</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0010-4825(20)30300-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.compbiomed.2020.103967</ELocationID>            <Abstract>                <AbstractText Label="AIMS">With a large number of fatalities, coronavirus disease-2019 (COVID-19) has greatly affected human health worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19. The World Health Organization has declared a global pandemic of this contagious disease. Researchers across the world are collaborating in a quest for remedies to combat this deadly virus. It has recently been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator by which the virus enters host cells.</AbstractText>                <AbstractText Label="MAIN METHODS">Our group comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis and a phylogenetic analysis. We predicted the strongest immunogenic epitopes of the SGP for both B cells and T cells.</AbstractText>                <AbstractText Label="KEY FINDINGS">We focused on predicting peptides that would bind major histocompatibility complex class I. Two optimal epitopes were identified, WTAGAAAYY and GAAAYYVGY. They interact with the HLA-B*15:01 allele, which was further validated by molecular docking simulation. This study also found that the selected epitopes are able to be recognized in a large percentage of the worlds population. Furthermore, we predicted CD4<sup>+</sup> T-cell epitopes and B-cell epitopes.</AbstractText>                <AbstractText Label="SIGNIFICANCE">Our study provides a strong basis for designing vaccine candidates against SARS-CoV-2. However, laboratory work is required to validate our theoretical results, which would lay the foundation for the appropriate vaccine manufacturing and testing processes.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rakib</LastName>                    <ForeName>Ahmed</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong, 4331, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sami</LastName>                    <ForeName>Saad Ahmed</ForeName>                    <Initials>SA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong, 4331, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mimi</LastName>                    <ForeName>Nusrat Jahan</ForeName>                    <Initials>NJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong, 4331, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chowdhury</LastName>                    <ForeName>Md Mustafiz</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong, 4331, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eva</LastName>                    <ForeName>Taslima Akter</ForeName>                    <Initials>TA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong, 4331, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nainu</LastName>                    <ForeName>Firzan</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Pharmacy, Hasanuddin University, Tamalanrea, Kota Makassar, Sulawesi Selatan, 90245, Indonesia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paul</LastName>                    <ForeName>Arkajyoti</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery, GUSTO A Research Group, Chittagong, 4203, Bangladesh; Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 4381, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shahriar</LastName>                    <ForeName>Asif</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology, Stamford University Bangladesh, 51 Siddeswari Road, Dhaka, 1217, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tareq</LastName>                    <ForeName>Abu Montakim</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, International Islamic University Chittagong, Chittagong, 4318, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Emon</LastName>                    <ForeName>Nazim Uddin</ForeName>                    <Initials>NU</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, International Islamic University Chittagong, Chittagong, 4318, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chakraborty</LastName>                    <ForeName>Sajal</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 4381, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shil</LastName>                    <ForeName>Sagar</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 4381, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mily</LastName>                    <ForeName>Sabrina Jahan</ForeName>                    <Initials>SJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynaecology and Obstetrics, Banshkhali Upazila Health Complex, Jaldi Union, Chittagong, 4390, Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ben Hadda</LastName>                    <ForeName>Taibi</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Applied Chemistry &amp; Environment, Faculty of Sciences, University Mohammed the First, BP 524, 60000, Oujda, Morocco; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah Almukkarramah, 21955, Saudi Arabia. Electronic address: taibi.ben.hadda@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Almalki</LastName>                    <ForeName>Faisal A</ForeName>                    <Initials>FA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah Almukkarramah, 21955, Saudi Arabia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Emran</LastName>                    <ForeName>Talha Bin</ForeName>                    <Initials>TB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 4381, Bangladesh. Electronic address: talhabmb@bgctub.ac.bd.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2020</Year>                <Month>08</Month>                <Day>13</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Comput Biol Med</MedlineTA>            <NlmUniqueID>1250250</NlmUniqueID>            <ISSNLinking>0010-4825</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D059910">HLA-B15 Antigen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059910" MajorTopicYN="N">HLA-B15 Antigen</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">COVID-19</Keyword>            <Keyword MajorTopicYN="Y">Epitope</Keyword>            <Keyword MajorTopicYN="Y">Immunoinformatics</Keyword>            <Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>            <Keyword MajorTopicYN="Y">Spike glycoprotein</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2020</Year>                <Month>05</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2020</Year>                <Month>08</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2020</Year>                <Month>08</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2020</Year>                <Month>8</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2020</Year>                <Month>9</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2020</Year>                <Month>8</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">32828069</ArticleId>            <ArticleId IdType="pii">S0010-4825(20)30300-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.compbiomed.2020.103967</ArticleId>            <ArticleId IdType="pmc">PMC7423576</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27899622</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Cheminform. 2011 Oct 07;3:33</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21982300</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Biomed Res Int. 2020 May 11;2020:2683286</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32461973</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2007 Dec 15;179(12):8243-51</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18056368</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 2020 Mar;579(7798):270-273</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32015507</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunology. 2016 Dec;149(4):386-399</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27485738</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Emerg Infect Dis. 2020 Jul;26(7):1470-1477</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32255761</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32187464</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Arthritis Rheum. 2000 Jan;43(1):155-63</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10643712</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Front Immunol. 2020 Jul 03;11:1581</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32719684</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2020 Mar 26;382(13):1199-1207</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">31995857</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Front Immunol. 2019 Feb 14;10:113</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">30837982</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunogenetics. 2011 Jun;63(6):325-35</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21305276</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nucleic Acids Res. 2015 Jul 1;43(W1):W580-4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25845596</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24324708</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunome Res. 2006 Apr 24;2:2</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16635264</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Biotechnol. 2006 Jul;24(7):817-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16767078</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32031570</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Annu Rev Biochem. 1978;47:251-76</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">354496</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Electrophoresis. 1997 Dec;18(15):2714-23</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9504803</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 2016 Sep 8;166(6):1459-1470.e11</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27610570</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Biomol Struct Dyn. 2020 May 13;:1-12</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32345124</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nucleic Acids Res. 2009 Jul;37(Web Server issue):W498-503</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19433514</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Protein Sci. 2003 May;12(5):1007-17</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12717023</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 2020 Apr 16;181(2):281-292.e6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32155444</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2020 Jul 3;369(6499):77-81</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32376603</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Eur Respir J. 2007 Jun;29(6):1246-55</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17540787</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Viruses. 2020 Feb 25;12(3):</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32106567</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Mol Immunol. 2014 Sep;61(1):16-22</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24853589</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2001 Jan 1;166(1):481-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11123327</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Bioinformatics. 2007 Sep 26;8:361</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17897458</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 1997 Apr 18;89(2):263-73</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9108481</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Bioinformatics. 2013;14 Suppl 6:S4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23735058</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Radiology. 2020 Apr;295(1):16-17</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32017662</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Virus Res. 2015 Aug 3;206:120-33</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25736566</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Infect Dis. 2020 Feb 22;20(1):172</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32087680</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Viruses. 2020 Jan 24;12(2):</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">31991541</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>EXCLI J. 2020 Mar 18;19:410-417</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32210742</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Bioinformatics. 2007 Jan 05;8:4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17207271</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>F1000Res. 2020 Feb 25;9:145</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32269766</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32004427</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>OMICS. 2011 Sep;15(9):625-36</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21732819</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Bioinformatics. 2013 Feb 14;14:52</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23409948</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Gen Virol. 2012 Jun;93(Pt 6):1185-1192</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22337639</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 1999 Oct;30(4):1037-44</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10498657</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Vaccines (Basel). 2020 Mar 29;8(2):</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32235387</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunol Res. 2007;39(1-3):94-104</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17917058</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Comput Chem. 2010 Jan 30;31(2):455-61</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19499576</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Dev Comp Immunol. 2000 Mar-Apr;24(2-3):269-83</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10717293</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Biomol Struct Dyn. 2020 Jun 1;:1-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32419646</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Exp Biol Med (Maywood). 2011 Mar;236(3):253-67</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21330360</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Rev Immunol. 2004 Aug;4(8):595-602</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15286726</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Sci Rep. 2019 Mar 13;9(1):4409</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">30867498</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Adv Virus Res. 2019;105:93-116</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">31522710</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Vaccine. 1995 Dec;13(18):1750-3</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8701588</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet. 1966 Jan 8;1(7428):76-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">4158999</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15474494</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 1985 Sep;55(3):836-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2991600</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32183941</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Thorac Dis. 2013 Aug;5 Suppl 2:S142-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23977435</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 2020 Aug 6;182(3):713-721.e9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32778225</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol Methods. 2013 Dec 31;400-401:30-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24144535</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Bioinformatics. 2006 Mar 17;7:153</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16545123</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 1997 May 22;387(6631):426-30</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9163431</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">30357391</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Biochem Biophys Res Commun. 2009 Jul 10;384(4):486-90</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19422787</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Med Virol. 2020 Jun;92(6):618-631</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32108359</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Bioinform Biol Insights. 2013 Nov 24;7:347-55</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24324329</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32007143</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dev Ctries. 2020 May 31;14(5):450-453</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">32525830</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>FEBS Lett. 1990 Dec 10;276(1-2):172-4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1702393</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):121-30</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20155490</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">22072759</PMID>        <DateCompleted>            <Year>2012</Year>            <Month>02</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1098-5514</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>86</Volume>                    <Issue>2</Issue>                    <PubDate>                        <Year>2012</Year>                        <Month>Jan</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of virology</Title>                <ISOAbbreviation>J Virol</ISOAbbreviation>            </Journal>            <ArticleTitle>Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope.</ArticleTitle>            <Pagination>                <MedlinePgn>991-1000</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.05603-11</ELocationID>            <Abstract>                <AbstractText>Antiviral CD8(+) T cells are a key component of the adaptive immune system against hepatitis C virus (HCV). For the development of immune therapies, it is essential to understand how CD8(+) T cells contribute to clearance of infection and why they fail so often. A mechanism for secondary failure is mutational escape of the virus. However, some substitutions in viral epitopes are associated with fitness costs and often require compensatory mutations. We hypothesized that compensatory mutations may point toward epitopes under particularly strong selection pressure that may be beneficial for vaccine design because of a higher genetic barrier to escape. We previously identified two HLA-B*15-restricted CD8(+) epitopes in NS5B (LLRHHNMVY(2450-2458) and SQRQKKVTF(2466-2474)), based on sequence analysis of a large HCV genotype 1b outbreak. Both epitopes are targeted in about 70% of HLA-B*15-positive individuals exposed to HCV. Reproducible selection of escape mutations was confirmed in an independent multicenter cohort in the present study. Interestingly, mutations were also selected in the epitope flanking region, suggesting that compensatory evolution may play a role. Covariation analysis of sequences from the database confirmed a significant association between escape mutations inside one of the epitopes (H2454R and M2456L) and substitutions in the epitope flanking region (S2439T and K2440Q). Functional analysis with the subgenomic replicon Con1 confirmed that the primary escape mutations impaired viral replication, while fitness was restored by the additional substitutions in the epitope flanking region. We concluded that selection of escape mutations inside an HLA-B*15 epitope requires secondary substitutions in the epitope flanking region that compensate for fitness costs.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ruhl</LastName>                    <ForeName>Marianne</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chhatwal</LastName>                    <ForeName>Patrick</ForeName>                    <Initials>P</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Strathmann</LastName>                    <ForeName>Heiko</ForeName>                    <Initials>H</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Kuntzen</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Bankwitz</LastName>                    <ForeName>Dorothea</ForeName>                    <Initials>D</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Skibbe</LastName>                    <ForeName>Kathrin</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Walker</LastName>                    <ForeName>Andreas</ForeName>                    <Initials>A</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Heinemann</LastName>                    <ForeName>Falko M</ForeName>                    <Initials>FM</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Horn</LastName>                    <ForeName>Peter A</ForeName>                    <Initials>PA</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Allen</LastName>                    <ForeName>Todd M</ForeName>                    <Initials>TM</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hoffmann</LastName>                    <ForeName>Daniel</ForeName>                    <Initials>D</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Pietschmann</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Timm</LastName>                    <ForeName>J\xc3\xb6rg</ForeName>                    <Initials>J</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>U19-AI082630</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AI067926</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U19 AI082630</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01-AI067926</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>P30 AI060354</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2011</Year>                <Month>11</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Virol</MedlineTA>            <NlmUniqueID>0113724</NlmUniqueID>            <ISSNLinking>0022-538X</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D016056">Immunodominant Epitopes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016056" MajorTopicYN="N">Immunodominant Epitopes</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2011</Year>                <Month>11</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2011</Year>                <Month>11</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2012</Year>                <Month>2</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">22072759</ArticleId>            <ArticleId IdType="pii">JVI.05603-11</ArticleId>            <ArticleId IdType="doi">10.1128/JVI.05603-11</ArticleId>            <ArticleId IdType="pmc">PMC3255842</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>J Virol. 2002 May;76(10):4792-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11967296</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2008 May 12;205(5):1009-17</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18426987</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2003 Mar;77(5):3007-19</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12584326</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2004 Apr 5;199(7):905-15</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15067030</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2004 Jul;78(13):7069-78</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15194783</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2004 Jul;40(1):87-97</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15239090</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2004 Jul;40(1):108-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15239092</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Invest. 2004 Jul;114(2):250-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15254592</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2004 Aug;78(16):8927-30</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15280502</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Methods Mol Biol. 1995;48:185-97</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8528391</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Med. 1997 Feb;3(2):212-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9018241</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Struct Biol. 1999 Oct;6(10):937-43</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10504728</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2004 Dec 20;200(12):1593-604</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15611288</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2005 Jun 6;201(11):1725-31</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15939788</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2005 Jun 6;201(11):1741-52</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15939790</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2005 Jun 6;201(11):1753-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15939791</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2005 Jul;42(1):104-12</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15962289</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2005 Oct 1;175(7):4618-26</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16177107</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2005 Oct;79(20):12979-88</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16189000</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2006 Mar;43(3):563-72</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16496339</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2006 May 15;203(5):1357-69</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16682496</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2006 Nov;80(22):11094-104</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17071929</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2007 Jan;81(2):945-53</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17079288</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2007 Mar;81(6):2545-53</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17182670</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Tissue Antigens. 2007 Apr;69 Suppl 1:10-2</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17445154</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2007 Aug;46(2):339-49</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17559151</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2007 Sep;81(17):9249-58</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17567698</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Blood. 2007 Sep 1;110(5):1559-69</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17475911</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2008;4(9):e1000143</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18773115</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2008 Dec;82(23):11803-12</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18815309</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2008 Dec;48(6):1769-78</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19026009</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Tissue Antigens. 2009 Feb;73(2):95-170</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19140825</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Invest. 2009 Feb;119(2):376-86</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19139562</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2009 Mar;83(6):2743-55</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19116253</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2009 Apr;83(8):3993-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19091871</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Invest. 2009 Jul;119(7):1745-54</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19587449</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2009 Sep;83(17):8616-27</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19515764</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2009 Sep;50(3):707-16</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19637188</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2010 Jan;84(1):492-502</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19828603</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2010 Feb;84(3):1656-63</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19906915</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2010;6(6):e1000947</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20548953</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2010 Aug;84(15):7581-91</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20504921</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2010 Nov;84(22):11937-49</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20810731</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Invest. 2010 Dec;120(12):4546-57</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21084749</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2011 Feb;53(2):396-405</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21246583</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Gastroenterology. 2011 Feb;140(2):686-696.e1</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20875418</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS One. 2011;6(4):e19018</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21544209</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Gastroenterology. 2011 Jun;140(7):2064-73</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21376049</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Gut. 2011 Nov;60(11):1563-71</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21551190</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2011 Nov;85(22):11883-90</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21880756</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>World J Gastroenterol. 2007 Sep 28;13(36):4808-17</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17828811</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2007 Nov;81(21):11658-68</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17699568</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hepatology. 2007 Dec;46(6):1713-21</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17935228</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Immunol. 2008;9:1</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18211710</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2002 Sep 15;169(6):3447-58</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12218168</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">27593217</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>01</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>01</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2059-2310</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>88</Volume>                    <Issue>4</Issue>                    <PubDate>                        <Year>2016</Year>                        <Month>10</Month>                    </PubDate>                </JournalIssue>                <Title>HLA</Title>                <ISOAbbreviation>HLA</ISOAbbreviation>            </Journal>            <ArticleTitle>Discovery of a novel HLA-B*15 allele, HLA-B*15:379, in a patient from Guinea-Bissau.</ArticleTitle>            <Pagination>                <MedlinePgn>203-4</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/tan.12873</ELocationID>            <Abstract>                <AbstractText>HLA-B*15:379 differs from HLA-B*15:03:01:01 by a c.T539G substitution in exon 3.</AbstractText>                <CopyrightInformation>\xc2\xa9 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Thomsen</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Christiansen</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">0000-0001-5158-3670</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark. Mette.Christiansen@rm.dk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Medina</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Erikstrup</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>H\xc3\xb8nge</LastName>                    <ForeName>B L</ForeName>                    <Initials>BL</Initials>                    <AffiliationInfo>                        <Affiliation>Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2016</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>HLA</MedlineTA>            <NlmUniqueID>101675570</NlmUniqueID>            <ISSNLinking>2059-2302</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D003062">Codon</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D059910">HLA-B15 Antigen</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003062" MajorTopicYN="N">Codon</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005091" MajorTopicYN="Y">Exons</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006169" MajorTopicYN="N">Guinea-Bissau</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015498" MajorTopicYN="N">HIV-2</DescriptorName>                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059910" MajorTopicYN="N">HLA-B15 Antigen</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D033162" MajorTopicYN="Y">Incidental Findings</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">HLA-B*15:379</Keyword>            <Keyword MajorTopicYN="Y">human leukocyte antigen</Keyword>            <Keyword MajorTopicYN="Y">next generation sequencing</Keyword>            <Keyword MajorTopicYN="Y">novel allele</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2016</Year>                <Month>08</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2016</Year>                <Month>08</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2016</Year>                <Month>08</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2016</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2016</Year>                <Month>9</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>1</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">27593217</ArticleId>            <ArticleId IdType="doi">10.1111/tan.12873</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">31589373</PMID>        <DateRevised>            <Year>2020</Year>            <Month>07</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2059-2310</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>95</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2020</Year>                        <Month>01</Month>                    </PubDate>                </JournalIssue>                <Title>HLA</Title>                <ISOAbbreviation>HLA</ISOAbbreviation>            </Journal>            <ArticleTitle>A novel allele HLA-B*15:02:01:04, recognized in an individual from the Angami tribe, Nagaland, North-East India.</ArticleTitle>            <Pagination>                <MedlinePgn>49-50</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/tan.13712</ELocationID>            <Abstract>                <AbstractText>A single nucleotide change (T to C) in HLA-B*15:02:01:01 results in the novel allele, HLA-B*15:02:01:04.</AbstractText>                <CopyrightInformation>\xc2\xa9 2019 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Keppen</LastName>                    <ForeName>Chenole</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Healthcare Laboratory and Research Centre, Naga Hospital Authority, Kohima, India.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Virology and Oncology, Department of Bioengineering and Technology, Gauhati University, Guwahati, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sharma</LastName>                    <ForeName>Akanksha</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Transplant Immunology and Immunogenetics, Clinical Immunogenetics Laboratory, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Medhi</LastName>                    <ForeName>Subhash</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Virology and Oncology, Department of Bioengineering and Technology, Gauhati University, Guwahati, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Khamo</LastName>                    <ForeName>Vinotsole</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Healthcare Laboratory and Research Centre, Naga Hospital Authority, Kohima, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kanga</LastName>                    <ForeName>Uma</ForeName>                    <Initials>U</Initials>                    <Identifier Source="ORCID">0000-0001-9437-0835</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Transplant Immunology and Immunogenetics, Clinical Immunogenetics Laboratory, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2019</Year>                <Month>10</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>HLA</MedlineTA>            <NlmUniqueID>101675570</NlmUniqueID>            <ISSNLinking>2059-2302</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">HLA-B</Keyword>            <Keyword MajorTopicYN="Y">Nagaland</Keyword>            <Keyword MajorTopicYN="Y">next-generation sequencing</Keyword>            <Keyword MajorTopicYN="Y">novel allele</Keyword>            <Keyword MajorTopicYN="Y">tribe</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2019</Year>                <Month>09</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2019</Year>                <Month>09</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2019</Year>                <Month>10</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2019</Year>                <Month>10</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2019</Year>                <Month>10</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2019</Year>                <Month>10</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">31589373</ArticleId>            <ArticleId IdType="doi">10.1111/tan.13712</ArticleId>        </ArticleIdList>        <ReferenceList>            <Title>REFERENCES</Title>            <Reference>                <Citation>Robinson J, Halliwell JA, Hayhurst JH, Flicek P, Parham P, Marsh SGE. The IPD and IMGT/HLA Database: allele variant databases. Nucleic Acids Res. 2015;43:D423-D431.</Citation>            </Reference>            <Reference>                <Citation>Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75:291-455.</Citation>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">22931407</PMID>        <DateCompleted>            <Year>2013</Year>            <Month>04</Month>            <Day>29</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>12</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1399-0039</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>80</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2012</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Tissue antigens</Title>                <ISOAbbreviation>Tissue Antigens</ISOAbbreviation>            </Journal>            <ArticleTitle>HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-\xce\xb1 and ribavirin.</ArticleTitle>            <Pagination>                <MedlinePgn>424-30</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-0039.2012.01956.x</ELocationID>            <Abstract>                <AbstractText>To investigate the relationship between human leukocyte antigen (HLA) class I and II alleles and treatment-induced anemia in chronic hepatitis C (CHC) patients receiving combination therapy with pegylated interferon-\xce\xb1 (PEG-IFN-\xce\xb1) and ribavirin (RBV). One hundred six na\xc3\xafve CHC patients (59 females and 47 males; mean age, 53.08 years) who underwent combination treatment were enrolled. The patients were considered positive for hemoglobin (Hb)-related side effects if the Hb concentrations dropped below 10 g/dl during PEG-IFN-\xce\xb1 plus RBV treatment. The HLA-A, -B, -C, -DR, and -DQ loci were investigated by sequence-based genotyping. The effects of the clinical characteristics, virologic variables, and the HLA alleles on treatment-induced anemia were evaluated by a logistic regression analysis. Forty patients (37.7%) had Hb levels below 10 g/dl during the treatment course. Low baseline Hb levels and an advanced liver fibrosis stage were associated with decreases in Hb levels to below 10 g/dl. The occurrence of treatment-related anemia (Hb &lt; 10 g/dl) was significantly associated with HLA-B*15:02 as shown by multivariate analysis (adjusted odds ratio, 8.13; 95% confidence interval: 1.19-55.70; P-value after Holms procedure, 0.03). HLA-B*15:02 is associated with treatment-induced anemia in Taiwanese CHC patients receiving combination therapy with PEG-IFN-\xce\xb1 plus RBV.</AbstractText>                <CopyrightInformation>\xc2\xa9 2012 John Wiley &amp; Sons A/S.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Tseng</LastName>                    <ForeName>C-W</ForeName>                    <Initials>CW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chia-Yi, Taiwan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hsieh</LastName>                    <ForeName>Y-H</ForeName>                    <Initials>YH</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Chang</LastName>                    <ForeName>C-K</ForeName>                    <Initials>CK</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Lai</LastName>                    <ForeName>N-S</ForeName>                    <Initials>NS</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hung</LastName>                    <ForeName>T-H</ForeName>                    <Initials>TH</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>S-F</ForeName>                    <Initials>SF</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Tseng</LastName>                    <ForeName>K-C</ForeName>                    <Initials>KC</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2012</Year>                <Month>08</Month>                <Day>30</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Tissue Antigens</MedlineTA>            <NlmUniqueID>0331072</NlmUniqueID>            <ISSNLinking>0001-2815</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C483536">HLA-B*15:02 antigen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D059910">HLA-B15 Antigen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>49717AWG6K</RegistryNumber>                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>Q46947FE7K</RegistryNumber>                <NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059910" MajorTopicYN="N">HLA-B15 Antigen</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2012</Year>                <Month>03</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2012</Year>                <Month>06</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2012</Year>                <Month>08</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2012</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2012</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2013</Year>                <Month>4</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">22931407</ArticleId>            <ArticleId IdType="doi">10.1111/j.1399-0039.2012.01956.x</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">22010883</PMID>        <DateCompleted>            <Year>2012</Year>            <Month>04</Month>            <Day>19</Day>        </DateCompleted>        <DateRevised>            <Year>2012</Year>            <Month>01</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1744-313X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>39</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2012</Year>                        <Month>Feb</Month>                    </PubDate>                </JournalIssue>                <Title>International journal of immunogenetics</Title>                <ISOAbbreviation>Int J Immunogenet</ISOAbbreviation>            </Journal>            <ArticleTitle>HLA-B*15:33, a rare allele whose product reacts as an HLA-B62 and -Cw5/Cw8 specificity.</ArticleTitle>            <Pagination>                <MedlinePgn>79-81</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1744-313X.2011.01050.x</ELocationID>            <Abstract>                <AbstractText>Using PCR with sequence-specific primers (SSP) and subsequent sequencing of exons 2 and 3, we identified an example of B*15:33 in a likely north-western European Caucasoid volunteer haemopoietic stem cell (HSC) donor. This was only the second example submitted to the IMGT/HLA database since B*15:33 was first described in 1996. B*15:33 differs from B*15:01:01:01 by three nucleotides resulting in two amino acid differences with B*15:01 (131S&gt;R, 138T&gt;K). This allele encodes a typical HLA-B62 specificity--as confirmed using 17 local antisera from parous women and 19 monoclonal antibodies directed towards B15, B62 and B63 specificities. Importantly, it also reacted as a Cw5/Cw8 specificity when tested against 21 Cw5, Cw5/Cw8 and Cw8 antisera. This Cw5/Cw8 reactivity is probably due to the B*15:33 specificity having lysine at position 138 which is possessed by numerous C*05 and many C*08 products. B*15:33 is likely to have derived from a HLA-B/C inter-locus gene conversion event. HLA-B*15:33 is clearly rare--this single example was found during the HLA PCR-SSP-based typing of 57,079 potential HSC donors. This indicates an allele frequency of &lt;0.00001 in blood donors resident in Wales. An Epstein-Barr virus transformed B-cell line from the HLA-B*15:33 donor is available.</AbstractText>                <CopyrightInformation>\xc2\xa9 2011 Blackwell Publishing Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Street</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Welsh Transplantation and Immunogenetics Laboratory, Welsh Blood Service, Pontyclun, Wales, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Climer</LastName>                    <ForeName>T</ForeName>                    <Initials>T</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Johnson</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Darke</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2011</Year>                <Month>10</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Int J Immunogenet</MedlineTA>            <NlmUniqueID>101232337</NlmUniqueID>            <ISSNLinking>1744-3121</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D059910">HLA-B15 Antigen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015236">HLA-C Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C037505">HLA-C*05 antigen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C524551">HLA-C*08 antigen</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000937" MajorTopicYN="Y">Antigen-Antibody Reactions</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000939" MajorTopicYN="Y">Epitopes</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059910" MajorTopicYN="N">HLA-B15 Antigen</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015236" MajorTopicYN="N">HLA-C Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014019" MajorTopicYN="N">Tissue Donors</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2011</Year>                <Month>10</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2011</Year>                <Month>10</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2012</Year>                <Month>4</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">22010883</ArticleId>            <ArticleId IdType="doi">10.1111/j.1744-313X.2011.01050.x</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">27226365</PMID>        <DateCompleted>            <Year>2017</Year>            <Month>06</Month>            <Day>02</Day>        </DateCompleted>        <DateRevised>            <Year>2020</Year>            <Month>12</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Electronic-Print">            <Journal>                <ISSN IssnType="Electronic">1098-5514</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>90</Volume>                    <Issue>15</Issue>                    <PubDate>                        <Year>2016</Year>                        <Month>08</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of virology</Title>                <ISOAbbreviation>J Virol</ISOAbbreviation>            </Journal>            <ArticleTitle>A Role of Influenza Virus Exposure History in Determining Pandemic Susceptibility and CD8+ T Cell Responses.</ArticleTitle>            <Pagination>                <MedlinePgn>6936-6947</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00349-16</ELocationID>            <Abstract>                <AbstractText Label="UNLABELLED">Novel influenza viruses often cause differential infection patterns across different age groups, an effect that is defined as heterogeneous demographic susceptibility. This occurred during the A/H2N2 pandemic, when children experienced higher influenza attack rates than adults. Since the recognition of conserved epitopes across influenza subtypes by CD8(+) cytotoxic T lymphocytes (CTLs) limit influenza disease, we hypothesized that conservation of CTL antigenic peptides (Ag-p) in viruses circulating before the pH2N2-1957 may have resulted in differential CTL immunity. We compared viruses isolated in the years preceding the pandemic (1941 to 1957) to which children and adults were exposed to viruses circulating decades earlier (1918 to 1940), which could infect adults only. Consistent with phylogenetic models, influenza viruses circulating from 1941 to 1957, which infected children, shared with pH2N2 the majority (\xe2\x88\xbc89%) of the CTL peptides within the most immunogenic nucleoprotein, matrix 1, and polymerase basic 1, thus providing evidence for minimal pH2N2 CTL escape in children. Our study, however, identified potential CTL immune evasion from pH2N2 irrespective of age, within HLA-A*03:01(+) individuals for PB1471-L473V/N476I variants and HLA-B*15:01(+) population for NP404-414-V408I mutant. Further experiments using the murine model of B-cell-deficient mice showed that multiple influenza infections resulted in superior protection from influenza-induced morbidity, coinciding with accumulation of tissue-resident memory CD8(+) T cells in the lung. Our study suggests that protection against H2N2-1957 pandemic influenza was most likely linked to the number of influenza virus infections prior to the pandemic challenge rather than differential preexisting CTL immunity. Thus, the regimen of a CTL-based vaccine/vaccine-component may benefit from periodic boosting to achieve fully protective, asymptomatic influenza infection.</AbstractText>                <AbstractText Label="IMPORTANCE">Due to a lack of cross-reactive neutralizing antibodies, children are particularly susceptible to influenza infections caused by novel viral strains. Preexisting T cell immunity directed at conserved viral regions, however, can provide protection against influenza viruses, promote rapid recovery and better clinical outcomes. When we asked whether high susceptibility of children (compared to adults) to the pandemic H2N2 influenza strain was associated with immune evasion from T-cell immunity, we found high conservation within T-cell antigenic regions in pandemic H2N2. However, the number of influenza infections prior to the challenge was linked to protective, asymptomatic infections and establishment of tissue-resident memory T cells. Our study supports development of vaccines that prime and boost T cells to elicit cross-strain protective T cells, especially tissue-resident memory T cells, for lifelong immunity against distinct influenza viruses.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2016, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Qui\xc3\xb1ones-Parra</LastName>                    <ForeName>Sergio M</ForeName>                    <Initials>SM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Clemens</LastName>                    <ForeName>E Bridie</ForeName>                    <Initials>EB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Zhongfang</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Croom</LastName>                    <ForeName>Hayley A</ForeName>                    <Initials>HA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kedzierski</LastName>                    <ForeName>Lukasz</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>The Walter and Eliza Hall Institute of Medical Research and Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McVernon</LastName>                    <ForeName>Jodie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vijaykrishna</LastName>                    <ForeName>Dhanasekaran</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Duke-NUS Medical School, Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kedzierska</LastName>                    <ForeName>Katherine</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia kkedz@unimelb.edu.au.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>HHSN272201400006C</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2016</Year>                <Month>07</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Virol</MedlineTA>            <NlmUniqueID>0113724</NlmUniqueID>            <ISSNLinking>0022-538X</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2016</Year>                <Month>02</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2016</Year>                <Month>05</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2016</Year>                <Month>5</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2016</Year>                <Month>5</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2017</Year>                <Month>6</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">27226365</ArticleId>            <ArticleId IdType="pii">JVI.00349-16</ArticleId>            <ArticleId IdType="doi">10.1128/JVI.00349-16</ArticleId>            <ArticleId IdType="pmc">PMC4944292</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>Nat Commun. 2013;4:2663</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24173108</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Immunol. 2013 Dec;14(12):1294-301</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24162776</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Gen Virol. 2007 Feb;88(Pt 2):530-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17251571</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2000 Aug;74(15):6800-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10888619</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dis. 2005 Jul 15;192(2):233-48</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15962218</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2014 Jun 1;192(11):5039-49</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24778446</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2008 Jun;82(11):5161-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18353950</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 1991 Apr 4;350(6317):423-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1901381</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Leukoc Biol. 2014 Feb;95(2):215-24</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24006506</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2012 Sep;86(18):10258; author reply1259-60</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22923812</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunol Cell Biol. 2013 Feb;91(2):184-94</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23399741</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Gen Virol. 1999 Dec;80 ( Pt 12):3167-71</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10567648</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dis. 2006 Jan 1;193(1):49-53</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16323131</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Epidemiol Rev. 1996;18(1):64-76</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8877331</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2015 Feb;89(4):2442-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25505070</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Commun. 2015 May 13;6:6833</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25967273</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Am J Hyg. 1948 Mar;47(2):142-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18908909</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet. 1951 Feb 3;1(6649):264-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">14795845</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2008 Feb 29;4(2):e1000012</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18463694</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Bull World Health Organ. 1952;6(3):287-315</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12988024</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11143-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12954978</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2015 Nov;89(22):11275-83</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26311880</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2014 Oct 3;346(6205):101-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25278612</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 1978 May 18;273(5659):238-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">306072</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 1983 Jul 7;309(1):13-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">6602294</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Front Microbiol. 2014 Jun 12;5:285</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24971078</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Vaccine. 2007 Jun 28;25(27):5086-96</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17544181</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2014 Feb;88(3):1684-93</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24257602</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2015 Nov 04;90(2):1009-22</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26537686</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2008 Dec;82(24):12241-51</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18842709</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2004 Feb 15;172(4):2453-60</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">14764717</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2013 Jul 29;210(8):1493-500</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23857983</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Acta Virol. 1992 Mar;36(2):113-20</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1279962</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 2012 Feb 29;483(7388):227-31</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22388819</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2002 Mar;76(5):2567-72</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11836437</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dis. 2005 Nov 15;192(10):1858-60; author reply 1860-2</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16235189</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 1990 Aug 16;346(6285):629-33</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1696684</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2005 May;79(9):5721-31</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15827187</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2011 May 31;108(22):9178-83</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21562214</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dis. 1997 Aug;176 Suppl 1:S14-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9240688</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12599-604</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20616031</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Med. 2013 Oct;19(10 ):1305-12</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24056771</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2002 May 24;296(5572):1439-43</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12029127</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Med. 2015 Jul;21(7):688-97</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26121195</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 2009 Jun 18;459(7249):931-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19525932</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11709-12</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19597152</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS One. 2015 Jun 18;10(6):e0129768</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26086392</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2015 Jun 19;348(6241):aaa8205</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26089520</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunol Cell Biol. 2007 Feb-Mar;85(2):85-92</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17213831</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10748-52</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12136133</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunity. 2011 May 27;34(5):781-93</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21549619</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2013 May 16;368(20):1862-4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23577629</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19745214</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Trends Microbiol. 2015 Apr;23(4):212-24</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25613992</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2014 Oct 3;346(6205):93-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25170048</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 1992 Apr 1;175(4):1143-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1552285</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2000 Dec;74(24):11690-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11090168</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Vaccine. 2009 Oct 23;27(45):6363-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19840674</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Immunol. 2013 Mar;14(3):238-45</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23354485</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 1998 Jan 1;160(1):322-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9551987</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Virus Res. 2004 Jul;103(1-2):97-100</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15163496</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Emerg Infect Dis. 2006 Apr;12(4):661-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16704816</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunity. 2010 Jul 23;33(1):128-40</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20619696</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2008 Sep 1;181(5):3486-94</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18714021</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2014 Oct 3;346(6205):98-101</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25170049</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Am J Respir Crit Care Med. 2015 Jun 15;191(12):1422-31</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25844934</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2006 Jul 15;177(2):831-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16818737</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2014 Jan;88(2):1175-88</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24227848</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2006 Jul 6;355(1):31-40</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16822994</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Sci Transl Med. 2012 Apr 4;4(128):128ra42</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22491952</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Protein Cell. 2010 Jan;1(1):9-13</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21203993</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Immunol. 2015 Apr;16(4):406-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25706747</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunity. 2013 Nov 14;39(5):939-48</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24238342</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Invest. 2008 Oct;118(10 ):3478-90</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18802496</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1049-54</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24395804</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">        <PMID Version="1">30396848</PMID>        <DateCompleted>            <Year>2020</Year>            <Month>02</Month>            <Day>24</Day>        </DateCompleted>        <DateRevised>            <Year>2020</Year>            <Month>03</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1477-2566</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>21</Volume>                    <Issue>2</Issue>                    <PubDate>                        <Year>2019</Year>                        <Month>02</Month>                    </PubDate>                </JournalIssue>                <Title>Cytotherapy</Title>                <ISOAbbreviation>Cytotherapy</ISOAbbreviation>            </Journal>            <ArticleTitle>Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.</ArticleTitle>            <Pagination>                <MedlinePgn>212-223</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1465-3249(18)30562-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcyt.2018.08.001</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND AIMS">EBV type II latency tumors, such as Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL) and nasopharyngeal carcinoma, express a limited array of EBV antigens including Epstein-Barr nuclear antigen (EBNA)1, latent membrane protein (LMP)1, LMP2, and BamH1-A right frame 1 (BARF1). Adoptive immunotherapy for these malignancies have focused on EBNA1, LMP1 and LMP2 because little is known about the cellular immune response to BARF1.</AbstractText>                <AbstractText Label="METHODS">To investigate whether BARF1 is a potential T-cell immunotherapy target, we determined the frequency of BARF1-specific T-cell responses in the peripheral blood of EBV-seropositive healthy donor and patients with EBV-positive malignancies, mapped epitopes and evaluated the effector function of ex vivo-generated BARF1-specific T-cell lines.</AbstractText>                <AbstractText Label="RESULTS">BARF1-specific T cells were present in the peripheral blood of 12/16 (75%) EBV-positive healthy donors and 13/20 (65%) patients with EBV-positive malignancies. Ex vivo expanded BARF1-specific T-cell lines contained CD4- and CD8-positive T-cell subpopulations, and we identified 23 BARF1 peptides, which encoded major histocompatibility complex class I- and/or II-restricted epitopes. Epitope mapping identified one human leukocyte antigen (HLA)-A*02-restricted epitope that was recognized by 50% of HLA-A*02, EBV-seropositive donors and one HLA-B*15(62)-restricted epitope. Exvivo expanded BARF1-specific T cells recognized and killed autologous, EBV-transformed lymphoblastoid cell lines and partially HLA-matched EBV-positive lymphoma cell lines.</AbstractText>                <AbstractText Label="DISCUSSION">BARF1 should be considered as an immunotherapy target for EBV type II (and III) latency. Targeting BARF1, in addition to EBNA1, LMP1 and LMP2, has the potential to improve the efficacy of current T-cell immunotherapy approaches for these malignancies.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2018 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kalra</LastName>                    <ForeName>Mamta</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gerdemann</LastName>                    <ForeName>Ulrike</ForeName>                    <Initials>U</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Luu</LastName>                    <ForeName>Jessica D</ForeName>                    <Initials>JD</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ngo</LastName>                    <ForeName>Minthran C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Leen</LastName>                    <ForeName>Ann M</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics; Pathology and Immunology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Louis</LastName>                    <ForeName>Chrystal U</ForeName>                    <Initials>CU</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rooney</LastName>                    <ForeName>Cliona M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics; Pathology and Immunology; Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gottschalk</LastName>                    <ForeName>Stephen</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Cell and Gene Therapy, Texas Childrens Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Childrens Cancer Center, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics; Pathology and Immunology. Electronic address: stephen.gottschalk@stjude.org.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P01 CA094237</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>P30 CA125123</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>P50 CA126752</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>                <PublicationType UI="D013486">Research Support, U.S. Govt, Non-P.H.S.</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cytotherapy</MedlineTA>            <NlmUniqueID>100895309</NlmUniqueID>            <ISSNLinking>1465-3249</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C086495">BARF1 protein, Human herpesvirus 4</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C063676">BZLF1 protein, Herpesvirus 4, Human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019309">Epstein-Barr Virus Nuclear Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>O5GA75RST7</RegistryNumber>                <NameOfSubstance UI="C417029">EBV-encoded nuclear antigen 1</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019309" MajorTopicYN="N">Epstein-Barr Virus Nuclear Antigens</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008223" MajorTopicYN="N">Lymphoma</DescriptorName>                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">BARF1</Keyword>            <Keyword MajorTopicYN="Y">EBV</Keyword>            <Keyword MajorTopicYN="Y">EBV-positive malignancies</Keyword>            <Keyword MajorTopicYN="Y">immunotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2020</Year>                <Month>2</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30396848</ArticleId>            <ArticleId IdType="pii">S1465-3249(18)30562-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.jcyt.2018.08.001</ArticleId>            <ArticleId IdType="pmc">PMC6435433</ArticleId>            <ArticleId IdType="mid">NIHMS1503330</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>J Immunother. 2010 Nov-Dec;33(9):983-90</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20948438</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Blood. 1998 Sep 1;92(5):1549-55</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9716582</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Mol Ther. 2011 Dec;19(12):2258-68</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21915103</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Virol J. 2008 Jun 04;5:70</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18533018</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Br J Haematol. 2003 Jun;121(5):805-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12780797</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2012 Dec;8(12):e1003095</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23300447</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Semin Cancer Biol. 2012 Apr;22(2):162-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22210180</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Biosci. 2015 Mar;40(1):41-51</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25740140</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cancer Res. 2000 Oct 1;60(19):5584-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11034107</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Annu Rev Immunol. 2015;33:787-821</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25706097</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Oncol. 2014 Mar 10;32(8):798-808</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24344220</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Blood. 2007 Oct 15;110(8):2838-45</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17609424</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Int J Cancer. 2008 Sep 1;123(5):1100-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18546263</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cancer Res Treat. 2011 Dec;43(4):250-4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22247711</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Rev Med Virol. 2013 Nov;23(6):367-83</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23996634</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cancer Res. 2012 Mar 1;72(5):1116-25</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22282657</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Eur J Immunol. 2013 Oct;43(10):2554-65</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23836147</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Oncol. 2013 Jan 1;31(1):39-48</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23169501</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunother. 2014 May;37(4):193-203</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24714353</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Blood. 2011 Apr 21;117(16):4304-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21304103</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2000 Aug 17;343(7):481-92</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10944566</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Blood. 2009 Mar 12;113(11):2442-50</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18971421</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Med Virol. 2005 May;76(1):82-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15778977</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Blood. 2001 Feb 1;97(3):708-13</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11157488</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Oncol. 2005 Dec 10;23(35):8942-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16204009</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Mol Ther. 2014 Jan;22(1):132-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24297049</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Blood. 2005 Mar 1;105(5):1898-904</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15542583</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Curr Top Microbiol Immunol. 2015;391:325-53</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26428380</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cancer Immunol Res. 2016 May;4(5):431-40</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27009165</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">        <PMID Version="1">31277607</PMID>        <DateCompleted>            <Year>2019</Year>            <Month>09</Month>            <Day>23</Day>        </DateCompleted>        <DateRevised>            <Year>2020</Year>            <Month>02</Month>            <Day>25</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2334</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>19</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2019</Year>                        <Month>Jul</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>BMC infectious diseases</Title>                <ISOAbbreviation>BMC Infect Dis</ISOAbbreviation>            </Journal>            <ArticleTitle>Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.</ArticleTitle>            <Pagination>                <MedlinePgn>583</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-019-4227-5</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human leukocyte antigen (HLA) alleles are implicated in drug-induced hypersensitivity, including by nevirapine and abacavir. The purpose of this meta-analysis was to evaluate the relationship between HLA polymorphisms and hypersensitivity to antiretroviral therapy in human immunodeficiency virus (HIV)-infected patients.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic search of PubMed, Embase, Web of Science, and the Cochrane Library for studies that evaluated the associations of HLA polymorphisms with antiretroviral therapy-induced hypersensitivity published in April 2019. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were considered as estimates of the effect.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The meta-analysis included 17 studies that assessed a total of 4273 patients. First, carriers of HLA-A *24 were associated with an increased risk of hypersensitivity among patients with HIV who received antiretroviral therapy (OR: 12.12; P\xe2\x80\x89=\xe2\x80\x890.018). Second, five SNPs of HLA-B genotypes, including *18 (OR: 1.63; P\xe2\x80\x89=\xe2\x80\x890.028), *35 (OR: 2.31; P\xe2\x80\x89=\xe2\x80\x890.002), *39 (OR: 11.85; P\xe2\x80\x89=\xe2\x80\x890.040), *51 (OR: 1.66; P\xe2\x80\x89=\xe2\x80\x890.028), and *81 (OR: 8.11; P\xe2\x80\x89=\xe2\x80\x890.021), were associated with an increased risk of hypersensitivity. Conversely, carriers of HLA-B *15 were associated with a reduced risk of hypersensitivity (OR: 0.43; P\xe2\x80\x89&lt;\xe2\x80\x890.001). Third, HLA-C *04 was associated with an increased risk of hypersensitivity (OR: 3.09; P\xe2\x80\x89&lt;\xe2\x80\x890.001), whereas a lower risk for hypersensitivity was observed in patients who were carriers of HLA-C *02 (OR: 0.22; P\xe2\x80\x89=\xe2\x80\x890.030), *03 (OR: 0.53; P\xe2\x80\x89=\xe2\x80\x890.049), and *07 (OR: 0.61; P\xe2\x80\x89=\xe2\x80\x890.044). Finally, carriers of HLA-DRB1 *05 (OR: 0.18; P\xe2\x80\x89=\xe2\x80\x890.006) and *15 (OR: 0.23; P\xe2\x80\x89=\xe2\x80\x890.013) were associated with a reduced risk of hypersensitivity among patients receiving antiretroviral therapy.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings of this meta-analysis indicated patients carrying HLA-A *24, HLA-B *18, *35, *39, *51, *81, HLA-C *04 were associated with a higher risk of hypersensitivity. Conversely, subjects carrying HLA-B *15, HLA-C *02, *03, *07, HLA-DRB1 *05, *15 were associated with a reduced risk of hypersensitivity.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Kun</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiang</LastName>                    <ForeName>Qian</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Zhe</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Peking University Health Science Center, 38# Xueyuan Road, Haidian District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mu</LastName>                    <ForeName>Guang-Yan</ForeName>                    <Initials>GY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Zhuo</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ma</LastName>                    <ForeName>Ling-Yue</ForeName>                    <Initials>LY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Qiu-Fen</ForeName>                    <Initials>QF</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Shu-Qing</ForeName>                    <Initials>SQ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Shuang</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Xiao-Dan</ForeName>                    <Initials>XD</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cui</LastName>                    <ForeName>Yi-Min</ForeName>                    <Initials>YM</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4186-1005</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, China. cui.pharm@pkufh.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>2016YFC0904900</GrantID>                    <Agency>National Key Technologies R&amp;D Program</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>81573504</GrantID>                    <Agency>National Natural Science Foundation of China</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>81673509</GrantID>                    <Agency>National Natural Science Foundation of China</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>7171012</GrantID>                    <Agency>Beijing Natural Science Foundation</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>2017ZX09304028</GrantID>                    <Agency>National Science and Technology Major Projects for &quot;Major New Drugs Innovation and Development&quot;</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>2017ZX09101001</GrantID>                    <Agency>National Science and Technology Major Projects for &quot;Major New Drugs Innovation and Development&quot;</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D017418">Meta-Analysis</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2019</Year>                <Month>07</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Infect Dis</MedlineTA>            <NlmUniqueID>100968551</NlmUniqueID>            <ISSNLinking>1471-2334</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015224">Dideoxynucleosides</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>99DK7FVK1H</RegistryNumber>                <NameOfSubstance UI="D019829">Nevirapine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>WR2TIP26VS</RegistryNumber>                <NameOfSubstance UI="C106538">abacavir</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015224" MajorTopicYN="N">Dideoxynucleosides</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019829" MajorTopicYN="N">Nevirapine</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Antiretroviral therapy</Keyword>            <Keyword MajorTopicYN="N">HIV</Keyword>            <Keyword MajorTopicYN="N">HLA</Keyword>            <Keyword MajorTopicYN="N">Hypersensitivity</Keyword>            <Keyword MajorTopicYN="N">Polymorphisms</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2019</Year>                <Month>06</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2019</Year>                <Month>7</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2019</Year>                <Month>7</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2019</Year>                <Month>9</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">31277607</ArticleId>            <ArticleId IdType="doi">10.1186/s12879-019-4227-5</ArticleId>            <ArticleId IdType="pii">10.1186/s12879-019-4227-5</ArticleId>            <ArticleId IdType="pmc">PMC6612203</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12958120</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4180-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15024131</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet. 2004 Apr 17;363(9417):1253-63</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15094269</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS. 2005 Jan 3;19(1):93-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15627039</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Med Decis Making. 2005 Nov-Dec;25(6):646-54</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16282215</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16625606</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS. 2006 Aug 1;20(12):1621-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16868443</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS. 2007 Jan 11;21(2):264-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17197830</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>N Engl J Med. 2008 Feb 7;358(6):568-79</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18256392</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS. 2008 Feb 19;22(4):539-40</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18301069</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Pharmacogenet Genomics. 2009 Feb;19(2):139-46</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19104471</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Pathobiology. 1991;59(5):324-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1910527</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Med. 2009 Jul 21;6(7):e1000097</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19621072</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS Res Ther. 2009 Oct 21;6:22</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19845952</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>JAMA. 2010 Jul 21;304(3):321-33</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20639566</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Trop Med Int Health. 2011 Feb;16(2):200-4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21091860</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS. 2011 Jun 19;25(10):1271-80</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21505298</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Pharmacol Pharmacother. 2011 Apr;2(2):114-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21772773</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):513-20</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21824325</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS Res Hum Retroviruses. 2012 Jun;28(6):540-3</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21902584</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Clin Pharmacol Ther. 2012 Apr;91(4):734-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22378157</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23328091</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Clin Infect Dis. 2013 May;56(9):1330-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23362284</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS. 2014 Aug 24;28(13):1891-901</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24911354</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Pharm Pharm Sci. 2015;18(1):68-76</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25877443</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet HIV. 2016 Feb;3(2):e64-75</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26847228</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Lancet HIV. 2017 Dec;4(12):e536-e546</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28729158</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Contact Dermatitis. 2017 Dec;77(6):379-384</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28782122</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Sci Rep. 2017 Aug 17;7(1):8653</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28819312</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Indian Pediatr. 2018 Feb 15;55(2):140-141</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29242412</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Invest. 2018 Jul 2;128(7):2819-2832</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29782330</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Control Clin Trials. 1986 Sep;7(3):177-88</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">3802833</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Biometrics. 1994 Dec;50(4):1088-101</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">7786990</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Med. 1996 Apr;2(4):405-11</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8597949</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9310563</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">31800372</PMID>        <DateCompleted>            <Year>2020</Year>            <Month>07</Month>            <Day>31</Day>        </DateCompleted>        <DateRevised>            <Year>2020</Year>            <Month>07</Month>            <Day>31</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1557-8976</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>32</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2019</Year>                        <Month>12</Month>                    </PubDate>                </JournalIssue>                <Title>Viral immunology</Title>                <ISOAbbreviation>Viral Immunol</ISOAbbreviation>            </Journal>            <ArticleTitle>Association of HLA-A, -B, DRB, and DQB Alleles with Persistent HPV-16 Infection in Women from Tamil Nadu, India.</ArticleTitle>            <Pagination>                <MedlinePgn>430-441</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1089/vim.2019.0094</ELocationID>            <Abstract>                <AbstractText>Women with persistent human papillomavirus (HPV) infections have a high risk of developing cervical cancer (CaCx). HPV-16 alone accounts for more than 60% of CaCx worldwide. Most of the HPV infections are transient and only a subset of women develop persistent HPV-16 infection. Many studies have shown associations of different human leukocyte antigen (HLA) alleles with HPV-mediated CaCx, but there are only a few studies globally that relate to persistent HPV-16 infection. Furthermore, such studies from India are sparse. Hence, we investigated the association of HLA-A, B, DRB, and DQB alleles with persistent HPV-16 infection and HPV-16-positive CaCx in south India (Tamil Nadu). HPV-16 persistent infection was observed in 7% of normal women. A total of 50 women with HPV-16-positive CaCx, 21 women with HPV-16 persistent infection, and 74 HPV-16-negative normal women were recruited for this study. Low-resolution typing of HLA-A, B, DRB, and DQB alleles was performed. HLA-B*44 and DRB1*07 showed a significant association with persistent HPV-16 infection (odds ratio, <i>p</i>-value\xe2\x80\x89=\xe2\x80\x8926.3, 0.03 and 4.7, 0.01, respectively). HLA-B*27 and DRB1*12 were significantly associated with both HPV-16<sup>+</sup> CaCx and persistent HPV-16 infection (23.8, 0.03; 52.9, 0.01; 9.8, 0.0009; and 13.8, 0.009; respectively). HLA-B*15 showed a negative association with HPV-16-positive CaCx (0.1, 0.01), whereas DRB1*04 exhibited protection to both HPV-16-positive CaCx and persistent HPV-16 infection (0.3, 0.0001 and 0.1, 0.0002, respectively). Thus, we show HLA allelic association with HPV-16 infection in Tamil Nadu. Larger studies on high-resolution HLA typing coupled with HPV-16 genome diversity will offer further insights into host/pathogen genome coevolution.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Bhaskaran</LastName>                    <ForeName>Muthumeenakshi</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genomics Laboratory, Centre for Research in Infectious Disease (CRID), School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Murali</LastName>                    <ForeName>Sree Varshini</ForeName>                    <Initials>SV</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genomics Laboratory, Centre for Research in Infectious Disease (CRID), School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rajaram</LastName>                    <ForeName>Barathi</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genomics Laboratory, Centre for Research in Infectious Disease (CRID), School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Krishnasamy</LastName>                    <ForeName>Sundar</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genomics Laboratory, Centre for Research in Infectious Disease (CRID), School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Devasena</LastName>                    <ForeName>C S</ForeName>                    <Initials>CS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynaecology, Kovai Medical Centre and Hospital, Coimbatore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pathak</LastName>                    <ForeName>Atima</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynaecology, Kovai Medical Centre and Hospital, Coimbatore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ravi</LastName>                    <ForeName>Vidhya</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynaecology, K.A.P. Viswanatham, Government Medical College, Tiruchirapalli, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Swaminathan</LastName>                    <ForeName>Krishnan</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Endocrinology, Kovai Medical Centre and Hospital and Research Foundation, Coimbatore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ayyappa</LastName>                    <ForeName>Ashok</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genomics Laboratory, Centre for Research in Infectious Disease (CRID), School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vedhantham</LastName>                    <ForeName>Srinivasan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of R&amp;D, MedGenome Labs Ltd., Bengaluru, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Seshachalam</LastName>                    <ForeName>Arun</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, GVN Hospital Ltd., Tiruchirapalli, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>ArunKumar</LastName>                    <ForeName>GaneshPrasad</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genomics Laboratory, Centre for Research in Infectious Disease (CRID), School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2019</Year>                <Month>12</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Viral Immunol</MedlineTA>            <NlmUniqueID>8801552</NlmUniqueID>            <ISSNLinking>0882-8245</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D006681">HLA-D Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002584" MajorTopicYN="N">Cervix Uteri</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName>                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006681" MajorTopicYN="N">HLA-D Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D052162" MajorTopicYN="N">Human papillomavirus 16</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">HLA</Keyword>            <Keyword MajorTopicYN="Y">HPV-16</Keyword>            <Keyword MajorTopicYN="Y">association studies</Keyword>            <Keyword MajorTopicYN="Y">cervical cancer</Keyword>            <Keyword MajorTopicYN="Y">persistent infection</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2019</Year>                <Month>12</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2020</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2019</Year>                <Month>12</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">31800372</ArticleId>            <ArticleId IdType="doi">10.1089/vim.2019.0094</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">22056847</PMID>        <DateCompleted>            <Year>2012</Year>            <Month>05</Month>            <Day>04</Day>        </DateCompleted>        <DateRevised>            <Year>2012</Year>            <Month>01</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1872-7492</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>163</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2012</Year>                        <Month>Jan</Month>                    </PubDate>                </JournalIssue>                <Title>Virus research</Title>                <ISOAbbreviation>Virus Res</ISOAbbreviation>            </Journal>            <ArticleTitle>The influence of HLA alleles and HBV subgenotyes on the outcomes of HBV infections in Northeast China.</ArticleTitle>            <Pagination>                <MedlinePgn>328-33</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2011.10.020</ELocationID>            <Abstract>                <AbstractText>Hepatitis B virus (HBV) infection has a wide variety of clinical outcomes, it could be spontaneouly recovered and also could develop fulminant liver failure or cirrhosis with hepatocellular carcinoma. Human leukocyte antigen (HLA) polymorphism and HBV (sub)genotypes have been speculated to associate with the outcome of HBV infection because the data obtained from various populations who bear different HLA alleles have shown a HLA polymorphism associated outcome of HBV infection. However, as the most important viral and host genetic factors, the impact of HBV (sub)genotypes in combination with HLA polymorphism on the clinical outcomes of HBV infections remains unclear. To demonstrate the association of HLA allele polymorphism in combination with HBV subgenotypes with the outcome of HBV infection in Northeastern Han Chinese population, a total of 230 HBV-infected individuals (Infection group) were compared to 210 random selected controls (Control group) who are negative for HBV infection for their HLA alleles frequency as well as the associations with the virus infection, clearance and persistence in combination with HBV subgenotypes. Of the 230 HBV-infected subjects, 54 were acute self-limited hepatitis (ASH) with HBV subgenotype C2 (ASH-C2), 144 were chronic hepatitis (CH) with HBV subgenotype C2 and B2 (CH-C2 and CH-B2), and 32 were spontaneously recovered (SR) without subgenotype results. When two groups are compared, the results suggest that B*48, B*51 and DRB1*12 carrier may have a high risk for HBV infection, but B*51 is likely association with spontaneous recovery and DRB1*07, 12 may be implied in viral persistence. HLA-B*15, DRB1*11 and 14 associated with viral clearance in the cases of HBV-C2 infection; HLA-B*54 carriers in chronic group are more sensitive to with the infection of HBV subgenotype B2; HLA-B*07 and DRB1*13 may protect subjects from HBV infection. The data presented a link between HLA polymorphism and HBV pathogenesis and suggested potential therapeutic targets for hepatitis B.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2011 Elsevier B.V. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xingku</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Research Center of the Second Affiliated Hospital of Harbin Medical University, Harbin, Peoples Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Wei</ForeName>                    <Initials>W</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Hongyan</ForeName>                    <Initials>H</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Jin</LastName>                    <ForeName>Xi</ForeName>                    <Initials>X</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Fang</LastName>                    <ForeName>Shaohong</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Yuguang</ForeName>                    <Initials>Y</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Zhen</ForeName>                    <Initials>Z</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Shuyun</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Shufen</ForeName>                    <Initials>S</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2011</Year>                <Month>10</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Virus Res</MedlineTA>            <NlmUniqueID>8410979</NlmUniqueID>            <ISSNLinking>0168-1702</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName>                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2011</Year>                <Month>06</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2011</Year>                <Month>10</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2011</Year>                <Month>10</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2011</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2011</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2012</Year>                <Month>5</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">22056847</ArticleId>            <ArticleId IdType="pii">S0168-1702(11)00414-X</ArticleId>            <ArticleId IdType="doi">10.1016/j.virusres.2011.10.020</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">27576480</PMID>        <DateCompleted>            <Year>2017</Year>            <Month>02</Month>            <Day>23</Day>        </DateCompleted>        <DateRevised>            <Year>2017</Year>            <Month>08</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1423-0097</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>170</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2016</Year>                    </PubDate>                </JournalIssue>                <Title>International archives of allergy and immunology</Title>                <ISOAbbreviation>Int Arch Allergy Immunol</ISOAbbreviation>            </Journal>            <ArticleTitle>HLA and Delayed Drug-Induced Hypersensitivity.</ArticleTitle>            <Pagination>                <MedlinePgn>163-79</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000448217</ELocationID>            <Abstract>                <AbstractText>Delayed drug allergy reactions (DDAR) are potentially fatal. Certain human leukocyte antigen (HLA) alleles have been associated with delayed allergy reactions following the administration of particular drugs. Examples are HLA-B*57:01 (abacavir), HLA-B*15:02/HLA-A*31:01 (carbamazepine), and HLA-B*58:01 (allopurinol). Based on the identification of these associations, it may now be possible to prevent certain allergy reactions that were, until recently, considered unpredictable. In this review, we will focus on the pharmacogenetics of the best-studied associations between specific HLA alleles and delayed allergy reactions and describe the pathogenesis models proposed so far. Finally, we will evaluate the genetic screening strategies available and discuss the clinical relevance of a better understanding of the immunogenetics and mechanisms involved in DDAR. </AbstractText>                <CopyrightInformation>\xc2\xa9 2016 S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sousa-Pinto</LastName>                    <ForeName>Bernardo</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Correia</LastName>                    <ForeName>Cl\xc3\xa1udia</ForeName>                    <Initials>C</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Gomes</LastName>                    <ForeName>L\xc3\xaddia</ForeName>                    <Initials>L</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Gil-Mata</LastName>                    <ForeName>Sara</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Ara\xc3\xbajo</LastName>                    <ForeName>Lu\xc3\xads</ForeName>                    <Initials>L</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Correia</LastName>                    <ForeName>Osvaldo</ForeName>                    <Initials>O</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Delgado</LastName>                    <ForeName>Lu\xc3\xads</ForeName>                    <Initials>L</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2016</Year>                <Month>08</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Int Arch Allergy Immunol</MedlineTA>            <NlmUniqueID>9211652</NlmUniqueID>            <ISSNLinking>1018-2438</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D006241">Haptens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D063926" MajorTopicYN="N">Drug Hypersensitivity Syndrome</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006241" MajorTopicYN="N">Haptens</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006968" MajorTopicYN="N">Hypersensitivity, Delayed</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013262" MajorTopicYN="N">Stevens-Johnson Syndrome</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2016</Year>                <Month>01</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2016</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2016</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2017</Year>                <Month>2</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">27576480</ArticleId>            <ArticleId IdType="pii">000448217</ArticleId>            <ArticleId IdType="doi">10.1159/000448217</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">        <PMID Version="1">33587436</PMID>        <DateCompleted>            <Year>2021</Year>            <Month>04</Month>            <Day>27</Day>        </DateCompleted>        <DateRevised>            <Year>2021</Year>            <Month>04</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1473-5571</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>35</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2021</Year>                        <Month>04</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>AIDS (London, England)</Title>                <ISOAbbreviation>AIDS</ISOAbbreviation>            </Journal>            <ArticleTitle>The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies.</ArticleTitle>            <Pagination>                <MedlinePgn>783-789</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0000000000002800</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES">The Strategic Timing of AntiRetroviral Treatment (START) and Strategies for Management of Antiretroviral Therapy (SMART) trials demonstrated that ART can partly reverse clinically defined immune dysfunction induced by HIV replication. As control of HIV replication is influenced by the HLA region, we explored whether HLA alleles independently influence the risk of clinical events in HIV+ individuals.</AbstractText>                <AbstractText Label="DESIGN">Cohort study.</AbstractText>                <AbstractText Label="METHODS">In START and SMART participants, associations between imputed HLA alleles and AIDS, infection-related cancer, herpes virus-related AIDS events, chronic inflammation-related conditions, and bacterial pneumonia were assessed. Cox regression was used to estimate hazard ratios for the risk of events among allele carriers versus noncarriers. Models were adjusted for sex, age, geography, race, time-updated CD4+ T-cell counts and HIV viral load and stratified by treatment group within trials. HLA class I and II alleles were analyzed separately. The Benjamini--Hochberg procedure was used to limit the false discovery rate to less than 5% (i.e. q value &lt;0.05).</AbstractText>                <AbstractText Label="RESULTS">Among 4829 participants, there were 132 AIDS events, 136 chronic inflammation-related conditions, 167 bacterial pneumonias, 45 infection-related cancers, and 49 herpes virus-related AIDS events. Several associations with q value less than 0.05 were found: HLA-DQB1\xe2\x88\x9706:04 and HLA-DRB1\xe2\x88\x9713:02 with AIDS (adjusted HR [95% CI] 2.63 [1.5-4.6] and 2.25 [1.4-3.7], respectively), HLA-B\xe2\x88\x9715:17 and HLA-DPB1\xe2\x88\x9715:01 with bacterial pneumonia (4.93 [2.3-10.7] and 4.33 [2.0-9.3], respectively), and HLA-A\xe2\x88\x9769:01 with infection-related cancer (15.26 [3.5-66.7]). The carriage frequencies of these alleles were 10% or less.</AbstractText>                <AbstractText Label="CONCLUSION">This hypothesis-generating study suggests that certain HLA alleles may influence the risk of immune dysfunction-related events irrespective of viral load and CD4+ T-cell count.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2020 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ekenberg</LastName>                    <ForeName>Christina</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Reekie</LastName>                    <ForeName>Joanne</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zucco</LastName>                    <ForeName>Adrian G</ForeName>                    <Initials>AG</Initials>                    <AffiliationInfo>                        <Affiliation>Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Murray</LastName>                    <ForeName>Daniel D</ForeName>                    <Initials>DD</Initials>                    <AffiliationInfo>                        <Affiliation>Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sharma</LastName>                    <ForeName>Shweta</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Macpherson</LastName>                    <ForeName>Cameron R</ForeName>                    <Initials>CR</Initials>                    <AffiliationInfo>                        <Affiliation>Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Babiker</LastName>                    <ForeName>Abdel</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council, Clinical Trials Unit in University College London, London, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kan</LastName>                    <ForeName>Virginia</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Veterans Affairs Medical Center and George Washington University, Washington DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lane</LastName>                    <ForeName>H Clifford</ForeName>                    <Initials>HC</Initials>                    <AffiliationInfo>                        <Affiliation>National Institute of Allergy and Infectious Diseases, Division of Clinical Research, Bethesda, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Neaton</LastName>                    <ForeName>James D</ForeName>                    <Initials>JD</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lundgren</LastName>                    <ForeName>Jens D</ForeName>                    <Initials>JD</Initials>                    <AffiliationInfo>                        <Affiliation>Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <CollectiveName>INSIGHT START, SMART Study Groups</CollectiveName>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>UM1 AI120197</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U01 AI068641</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U01 AI046362</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>UM1 AI068641</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U01 AI136780</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U01 AI042170</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>AIDS</MedlineTA>            <NlmUniqueID>8710219</NlmUniqueID>            <ISSNLinking>0269-9370</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <CitationSubset>X</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName>                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pmc-release">                <Year>2022</Year>                <Month>04</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2021</Year>                <Month>2</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2021</Year>                <Month>4</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2021</Year>                <Month>2</Month>                <Day>15</Day>                <Hour>14</Hour>                <Minute>3</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">33587436</ArticleId>            <ArticleId IdType="doi">10.1097/QAD.0000000000002800</ArticleId>            <ArticleId IdType="pii">00002030-202104010-00009</ArticleId>            <ArticleId IdType="pmc">PMC7969421</ArticleId>            <ArticleId IdType="mid">NIHMS1661859</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>Tian C, Hromatka BS, Kiefer AK, Eriksson N, Noble SM, Tung JY, Hinds DA. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nat Commun 2017; 8:599.</Citation>            </Reference>            <Reference>                <Citation>Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat Rev Genet 2012; 13:175\xe2\x80\x93188.</Citation>            </Reference>            <Reference>                <Citation>Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551\xe2\x80\x931557.</Citation>            </Reference>            <Reference>                <Citation>Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet 2013; 14:301\xe2\x80\x93323.</Citation>            </Reference>            <Reference>                <Citation>Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999; 167:257\xe2\x80\x93274.</Citation>            </Reference>            <Reference>                <Citation>Cortes A, Albers PK, Dendrou CA, Fugger L, McVean G. Identifying cross-disease components of genetic risk across hospital data in the UK Biobank. Nat Genet 2020; 52:126\xe2\x80\x93134.</Citation>            </Reference>            <Reference>                <Citation>Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944\xe2\x80\x93947.</Citation>            </Reference>            <Reference>                <Citation>Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.</Citation>            </Reference>            <Reference>                <Citation>McLaren PJ, Carrington M. The impact of host genetic variation on infection with HIV-1. Nat Immunol 2015; 16:577\xe2\x80\x93583.</Citation>            </Reference>            <Reference>                <Citation>McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, et al. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proc Natl Acad Sci U S A 2015; 112:14658\xe2\x80\x9314663.</Citation>            </Reference>            <Reference>                <Citation>McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington M, et al. Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog 2013; 9:e1003515.</Citation>            </Reference>            <Reference>                <Citation>McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, et al. Evaluating the impact of functional genetic variation on HIV-1 control. J Infect Dis 2017; 216:1063\xe2\x80\x931069.</Citation>            </Reference>            <Reference>                <Citation>Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, et al. Association between single-nucleotide polymorphisms in hla alleles and human immunodeficiency virus type 1 viral load in demographically diverse, antiretroviral therapy-naive participants from the strategic timing of antiretroviral treatment Trial. J Infect Dis 2019; 220:1325\xe2\x80\x931334.</Citation>            </Reference>            <Reference>                <Citation>Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B\xe2\x88\x975701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709\xe2\x80\x932714.</Citation>            </Reference>            <Reference>                <Citation>Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167\xe2\x80\x931170.</Citation>            </Reference>            <Reference>                <Citation>Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405\xe2\x80\x93411.</Citation>            </Reference>            <Reference>                <Citation>Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769\xe2\x80\x93775.</Citation>            </Reference>            <Reference>                <Citation>Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, Shianna KV, et al. Infectious Disease Clinical Research Program HIV Working Group, National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology (CHAVI). Host determinants of HIV-1 control in African Americans. J Infect Dis 2010; 201:1141\xe2\x80\x931149.</Citation>            </Reference>            <Reference>                <Citation>World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd edition.Geneva: WHO; 2016.</Citation>            </Reference>            <Reference>                <Citation>Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795\xe2\x80\x93807.</Citation>            </Reference>            <Reference>                <Citation>El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283\xe2\x80\x932296.</Citation>            </Reference>            <Reference>                <Citation>Borges AH, Neuhaus J, Sharma S, Neaton JD, Henry K, Anagnostou O, et al. INSIGHT SMART, START Study Groups. The effect of interrupted/deferred antiretroviral therapy on disease risk: a SMART and START combined analysis. J Infect Dis 2019; 219:254\xe2\x80\x93263.</Citation>            </Reference>            <Reference>                <Citation>Lifson AR, Rhame FS, Belloso WH, Dragsted UB, El-Sadr WM, Gatell JM, et al. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV clinical trials 2006; 7:125\xe2\x80\x93141.</Citation>            </Reference>            <Reference>                <Citation>Hart BB, Nordell AD, Okulicz JF, Palfreeman A, Horban A, Kedem E, et al. Inflammation-related morbidity and mortality among HIV-positive adults: how extensive is it?. J Acquir Immune Defic Syndr 19992018; 77:1\xe2\x80\x937.</Citation>            </Reference>            <Reference>                <Citation>Zheng X, Shen J, Cox C, Wakefield JC, Ehm MG, Nelson MR, Weir BS. HIBAG--HLA genotype imputation with attribute bagging. Pharmacogenomics J 2014; 14:192\xe2\x80\x93200.</Citation>            </Reference>            <Reference>                <Citation>Costello C, Tang J, Rivers C, Karita E, Meizen-Derr J, Allen S, et al. HLA-B\xe2\x88\x975703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS (London, England) 1999; 13:1990\xe2\x80\x931991.</Citation>            </Reference>            <Reference>                <Citation>Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B\xe2\x88\x9735-Cw\xe2\x88\x9704 disadvantage. Science 1999; 283:1748\xe2\x80\x931752.</Citation>            </Reference>            <Reference>                <Citation>Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol 2013; 31:443\xe2\x80\x93473.</Citation>            </Reference>            <Reference>                <Citation>Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature genetics 1994; 6:157\xe2\x80\x93162.</Citation>            </Reference>            <Reference>                <Citation>Shim H, Park B, Shin HJ, Joo J, Yoon KA, Kim YM, et al. Protective association of HLA-DRB1\xe2\x88\x9713:02, HLA-DRB1\xe2\x88\x9704:06, and HLA-DQB1\xe2\x88\x9706:04 alleles with cervical cancer in a Korean population. Hum Immunol 2019; 80:107\xe2\x80\x93111.</Citation>            </Reference>            <Reference>                <Citation>Chambuso R, Ramesar R, Kaambo E, Denny L, Passmore JA, Williamson AL, et al. Human leukocyte antigen (HLA) class II -DRB1 and -DQB1 alleles and the association with cervical cancer in HIV/HPV co-infected women in South Africa. J Cancer 2019; 10:2145\xe2\x80\x932152.</Citation>            </Reference>            <Reference>                <Citation>Louie LG, Hartogensis WE, Jackman RP, Schultz KA, Zijenah LS, Yiu CH, et al. Mycobacterium tuberculosis/HIV-1 coinfection and disease: role of human leukocyte antigen variation. J Infect Dis 2004; 189:1084\xe2\x80\x931090.</Citation>            </Reference>            <Reference>                <Citation>Cornejo Castro EM, Morrison BJ, Marshall VA, Labo N, Miley WJ, Clements N, et al. Relationship between human leukocyte antigen alleles and risk of Kaposis sarcoma in Cameroon. Genes Immun 2019; 20:684\xe2\x80\x93689.</Citation>            </Reference>            <Reference>                <Citation>Marmor M, Winchester R, Zeleniuch-Jacquotte A, Weiss SH, Krasinski K, Saxinger WC, et al. Evidence for an effect of human leukocyte antigens on susceptibility to Kaposis sarcoma related to charge and peptide-binding properties of class I molecules. AIDS 1995; 9:1194\xe2\x80\x931195.</Citation>            </Reference>            <Reference>                <Citation>Yasunami M, Nakamura H, Tokunaga K, Kawashima M, Nishida N, Hitomi Y, et al. Principal contribution of HLA-DQ alleles, DQB1\xe2\x88\x9706:04 and DQB1\xe2\x88\x9703:01, to disease resistance against primary biliary cholangitis in a Japanese population. Sci Rep 2017; 7:11093.</Citation>            </Reference>            <Reference>                <Citation>Martinetti M, Biagi F, Badulli C, Feurle GE, Muller C, Moos V, et al. The HLA alleles DRB1\xe2\x88\x9713 and DQB1\xe2\x88\x9706 are associated to Whipples disease. Gastroenterology 2009; 136:2289\xe2\x80\x932294.</Citation>            </Reference>            <Reference>                <Citation>Gyllensten UB, Erlich HA. MHC class II haplotypes and linkage disequilibrium in primates. Hum Immunol 1993; 36:1\xe2\x80\x9310.</Citation>            </Reference>            <Reference>                <Citation>Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol 1992; 148:249\xe2\x80\x93258.</Citation>            </Reference>            <Reference>                <Citation>Pant Pai N, Shivkumar S, Cajas JM. Does genetic diversity of HIV-1 non-B subtypes differentially impact disease progression in treatment-naive HIV-1-infected individuals? A systematic review of evidence: 1996-2010. J Acquir Immune Defic Syndr 2012; 59:382\xe2\x80\x93388.</Citation>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">28268260</PMID>        <DateCompleted>            <Year>2017</Year>            <Month>05</Month>            <Day>01</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>01</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0215</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>140</Volume>                    <Issue>11</Issue>                    <PubDate>                        <Year>2017</Year>                        <Month>06</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of cancer</Title>                <ISOAbbreviation>Int J Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis.</ArticleTitle>            <Pagination>                <MedlinePgn>2498-2508</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.30681</ELocationID>            <Abstract>                <AbstractText>In a novel attempt to understand the variations in DNA sequences underlying HLA class I alleles associated with HPV16-related CaCx, we determined the alleles by reconstructing SNP-based haplotypes from resequencing of the most polymorphic exons 2 and 3 of HLA-A, HLA-B and HLA-C. We also determined the impact of SNPs and transcriptional alterations of the genes on CaCx. A high density of SNPs was identified from resequencing. HLA expression was determined by real-time PCR. We identified that even a single associated HLA allele had many underlying SNP-based haplotypes. Out of the most frequent (\xe2\x89\xa55%) HLA class I alleles, HLA-B*40:06 and HLA-B*15:02 respectively imparted significant risk towards and protection from CaCx as well as HPV16 infection. Employing median-joining networks to detect clusters of sequence-variations for specific HLA alleles, we found the protective SNP-based signature, GAATTTA, in all SNP-based haplotypes of HLA-B*15:02 allele. The signature was derived from seven SNPs within HLA-B which were newly associated with the disease. Contrarily, similarly derived risk-signature, TTGCGCC, mapped only to 52% of SNP-based haplotypes of HLA-B*40:06 allele. This indicated that all SNP-based haplotypes underlying a particular associated HLA allele might or might not have a single signature of risk/protection. HLA-A, HLA-B and HLA-C expressions were downregulated among CaCx cases compared to asymptomatic infections and HPV-negative controls. HLA-A and HLA-B were repressed in both cases harbouring episomal and integrated HPV16, whereas HLA-C in only the latter. Novel genetic variations and differential downregulation-patterns of HLA class I have a significant bearing on HPV16-related CaCx pathogenesis.</AbstractText>                <CopyrightInformation>\xc2\xa9 2017 UICC.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Das Ghosh</LastName>                    <ForeName>Damayanti</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genetics Unit, Indian Statistical Institute, Kolkata, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mukhopadhyay</LastName>                    <ForeName>Indranil</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Human Genetics Unit, Indian Statistical Institute, Kolkata, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bhattacharya</LastName>                    <ForeName>Amrapali</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Genomics and Epigenomics, National Institute of Biomedical Genomics, Netaji Subhas Sanatorium, Kalyani, West Bengal, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roy Chowdhury</LastName>                    <ForeName>Rahul</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology, Saroj Gupta Cancer Centre and Research Institute, Kolkata, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mandal</LastName>                    <ForeName>Nidhu Ranjan</ForeName>                    <Initials>NR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology, Saroj Gupta Cancer Centre and Research Institute, Kolkata, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roy</LastName>                    <ForeName>Sudipta</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Sri Aurobindo Seva Kendra, Kolkata, West Bengal, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sengupta</LastName>                    <ForeName>Sharmila</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">0000-0003-2462-5198</Identifier>                    <AffiliationInfo>                        <Affiliation>Cancer Genomics and Epigenomics, National Institute of Biomedical Genomics, Netaji Subhas Sanatorium, Kalyani, West Bengal, India.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2017</Year>                <Month>03</Month>                <Day>24</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Cancer</MedlineTA>            <NlmUniqueID>0042124</NlmUniqueID>            <ISSNLinking>0020-7136</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015236">HLA-C Antigens</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005805" MajorTopicYN="N">Genes, MHC Class I</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015236" MajorTopicYN="N">HLA-C Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D052162" MajorTopicYN="N">Human papillomavirus 16</DescriptorName>                <QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName>                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">HLA class I alleles</Keyword>            <Keyword MajorTopicYN="Y">HPV16</Keyword>            <Keyword MajorTopicYN="Y">SNP</Keyword>            <Keyword MajorTopicYN="Y">cervical cancer</Keyword>            <Keyword MajorTopicYN="Y">differential expression</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2016</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2017</Year>                <Month>02</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2017</Year>                <Month>3</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2017</Year>                <Month>5</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2017</Year>                <Month>3</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">28268260</ArticleId>            <ArticleId IdType="doi">10.1002/ijc.30681</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">29995954</PMID>        <DateCompleted>            <Year>2019</Year>            <Month>01</Month>            <Day>14</Day>        </DateCompleted>        <DateRevised>            <Year>2021</Year>            <Month>01</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1553-7374</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>14</Volume>                    <Issue>7</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>07</Month>                    </PubDate>                </JournalIssue>                <Title>PLoS pathogens</Title>                <ISOAbbreviation>PLoS Pathog</ISOAbbreviation>            </Journal>            <ArticleTitle>Selected HLA-B allotypes are resistant to inhibition or deficiency of the transporter associated with antigen processing (TAP).</ArticleTitle>            <Pagination>                <MedlinePgn>e1007171</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1007171</ELocationID>            <Abstract>                <AbstractText>Major histocompatibility complex class I (MHC-I) molecules present antigenic peptides to CD8+ T cells, and are also important for natural killer (NK) cell immune surveillance against infections and cancers. MHC-I molecules are assembled via a complex assembly pathway in the endoplasmic reticulum (ER) of cells. Peptides present in the cytosol of cells are transported into the ER via the transporter associated with antigen processing (TAP). In the ER, peptides are assembled with MHC-I molecules via the peptide-loading complex (PLC). Components of the MHC-I assembly pathway are frequently targeted by viruses, in order to evade host immunity. Many viruses encode inhibitors of TAP, which is thought to be a central source of peptides for the assembly of MHC-I molecules. However, human MHC-I (HLA-I) genes are highly polymorphic, and it is conceivable that several variants can acquire peptides via TAP-independent pathways, thereby conferring resistance to pathogen-derived inhibitors of TAP. To broadly assess TAP-independent expression within the HLA-B locus, expression levels of 27 frequent HLA-B alleles were tested in cells with deficiencies in TAP. Approximately 15% of tested HLA-B allotypes are expressed at relatively high levels on the surface of TAP1 or TAP2-deficient cells and occur in partially peptide-receptive forms and Endoglycosidase H sensitive forms on the cell surface. Synergy between high peptide loading efficiency, broad specificity for peptides prevalent within unconventional sources and high intrinsic stability of the empty form allows for deviations from the conventional HLA-I assembly pathway for some HLA-B*35, HLA-B*57 and HLA-B*15 alleles. Allotypes that display higher expression in TAP-deficient cells are more resistant to viral TAP inhibitor-induced HLA-I down-modulation, and HLA-I down-modulation-induced NK cell activation. Conversely, the same allotypes are expected to mediate stronger CD8+ T cell responses under TAP-inhibited conditions. Thus, the degree of resistance to TAP inhibition functionally separates specific HLA-B allotypes.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Geng</LastName>                    <ForeName>Jie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zaitouna</LastName>                    <ForeName>Anita J</ForeName>                    <Initials>AJ</Initials>                    <Identifier Source="ORCID">0000-0001-5513-6886</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Raghavan</LastName>                    <ForeName>Malini</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">0000-0002-1345-9318</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Immunology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>Dryad</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>10.5061/dryad.m4862mk</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>R01 AI044115</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R21 AI126054</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R56 AI044115</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>PLoS Pathog</MedlineTA>            <NlmUniqueID>101238921</NlmUniqueID>            <ISSNLinking>1553-7366</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C477327">transporter associated with antigen processing (TAP)</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007157" MajorTopicYN="N">Immunologic Surveillance</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2019</Year>                <Month>1</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">29995954</ArticleId>            <ArticleId IdType="doi">10.1371/journal.ppat.1007171</ArticleId>            <ArticleId IdType="pii">PPATHOGENS-D-18-00151</ArticleId>            <ArticleId IdType="pmc">PMC6056074</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>J Clin Invest. 2016 Dec 1;126(12):4690-4701</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27841757</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Cell Sci. 2014 Jul 1;127(Pt 13):2885-97</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24806963</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Biol Chem. 2003 Apr 25;278(17):15291-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12582163</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>EMBO J. 2009 Dec 2;28(23):3730-44</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19851281</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Int Immunol. 1990;2(2):113-25</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2088481</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Eur J Immunol. 2008 Jun;38(6):1503-10</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18446792</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS One. 2016 Sep 20;11(9):e0163297</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27649529</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Genome Biol. 2017 Apr 27;18(1):76</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28449694</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Front Immunol. 2017 Feb 08;8:65</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28228754</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2007 Aug 6;204(8):1863-73</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17620360</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Methods. 2005 Apr;35(4):373-81</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15804610</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 1994 Jul 8;265(5169):237-41</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">7517574</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2011 Mar 1;186(5):2990-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21270408</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2015 Apr 16;11(4):e1004743</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25880312</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunity. 2002 Apr;16(4):509-20</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11970875</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2001 Aug 1;167(3):1212-21</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11466336</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2004 Jul 5;200(1):13-24</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15226359</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Med. 2006 Apr;12(4):417-24</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16550190</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 1990 Aug 10;62(3):563-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2199065</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 1992 Mar 6;255(5049):1264-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1546329</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Eur J Immunol. 2015 Apr;45(4):1248-57</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">25615938</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 1991 May 1;88(9):3594-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2023907</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Immunol. 2000 Sep;1(3):234-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10973281</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Protein Sci. 2007 Feb;16(2):299-308</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17242432</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>FASEB J. 2011 Nov;25(11):3989-98</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21836024</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2016 Feb 15;196(4):1711-20</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26792804</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 1996 May 1;156(9):3196-206</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8617941</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Rev Immunol. 2009 Jul;9(7):503-13</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19498380</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 1990 Aug 2;346(6283):476-80</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2198471</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Struct Biol. 1998 May;5(5):377-84</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9587000</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Protein Sci. 2003 May;12(5):1007-17</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12717023</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Biol Chem. 2006 Dec 29;281(52):39839-51</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17068338</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell. 1992 Dec 24;71(7):1205-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1473153</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2006 Sep 1;177(5):3150-61</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16920953</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):8976-81</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9256420</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Trends Immunol. 2008 Sep;29(9):436-43</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18675588</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 2012 Jul 26;487(7408):491-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22810586</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Clin Exp Immunol. 2002 Jun;128(3):525-31</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12067308</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nature. 1992 Apr 2;356(6368):443-6</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1557127</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunity. 1998 May;8(5):531-42</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9620674</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">9560253</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8265660</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2017 Nov 24;358(6366):1060-1064</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29025996</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Bioinformatics. 2016 Feb 15;32(4):511-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26515819</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2010 Dec 1;185(11):6508-17</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20980626</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 1995 Feb 1;154(3):1273-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">7822796</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunity. 2017 Feb 21;46(2):315-326</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">28228285</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Clin Invest. 2016 Feb;126(2):784-94</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26784543</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Elife. 2018 May 09;7:</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29741477</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>FEBS Lett. 1994 Sep 12;351(3):443-7</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8082812</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2000 Jul 1;165(1):322-30</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10861068</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Immunol. 2016 Sep;17(9):1067-74</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">27455421</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 2017 Nov 24;358(6366):1064-1068</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29025991</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 1994 Oct 1;180(4):1235-42</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">7931060</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2015 Nov 1;195(9):4503-13</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">26416272</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Annu Rev Immunol. 1999;17:739-79</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10358773</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23852952</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunogenetics. 2009 Dec;61(11-12):703-16</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19838694</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 1992 Dec 4;258(5088):1658-62</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">1360705</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Biomed Biotechnol. 2011;2011:298348</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21629750</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Exp Med. 2001 Oct 15;194(8):1053-68</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11602636</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Immunol. 2008 Jan 22;9:1</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18211710</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 1996 May 1;156(9):3308-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8617954</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2018 Jul 11;14(7):e1007171</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">29995954</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2013 Oct 1;191(7):3553-62</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24018270</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2014 Jun 1;192(11):4967-76</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24790147</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Eur J Immunol. 1990 Apr;20(4):759-64</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2189736</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Rev Med Virol. 2014 Nov;24(6):365-78</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">24733560</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">24015196</PMID>        <DateCompleted>            <Year>2014</Year>            <Month>05</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1932-6203</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2013</Year>                    </PubDate>                </JournalIssue>                <Title>PloS one</Title>                <ISOAbbreviation>PLoS One</ISOAbbreviation>            </Journal>            <ArticleTitle>Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M.</ArticleTitle>            <Pagination>                <MedlinePgn>e71888</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0071888</ELocationID>            <Abstract>                <AbstractText>The combination of host immune responses and use of antiretrovirals facilitate partial control of human immunodeficiency virus type 1 (HIV-1) infection and result in delayed progression to Acquired Immunodeficiency Syndrome (AIDS). Both treatment and host immunity impose selection pressures on the highly mutable HIV-1 genome resulting in antiretroviral resistance and immune escape. Researchers have shown that antiretroviral resistance mutations can shape cytotoxic T-lymphocyte immunity by altering the epitope repertoire of HIV infected cells. Here it was discovered that an important antiretroviral resistance mutation, L90M in HIV protease, occurs at lower frequencies in hosts that harbor the B*15, B*48 or A*32 human leukocyte antigen subtypes. A likely reason is the elucidation of novel epitopes by L90M. NetMHCPan predictions reveal increased affinity of the peptide spanning the HIV protease region, PR 89-97 and PR 90-99 to HLA-B*15/B*48 and HLA-A*32 respectively due to the L90M substitution. The higher affinity could increase the chance of the epitope being presented and recognized by Cytotoxic T-lymphocytes and perhaps provide additional immunological pressures in the presence of antiretroviral attenuating mutations. This evidence supports the notion that knowledge of HLA allotypes in HIV infected individuals could augment antiretroviral treatment by the elucidation of epitopes due to antiretroviral resistance mutations in HIV protease. </AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Smidt</LastName>                    <ForeName>Werner</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Bioinformatics and Computational Biology Unit, Department of Biochemistry, University of Pretoria, Pretoria, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2013</Year>                <Month>08</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>PLoS One</MedlineTA>            <NlmUniqueID>101285081</NlmUniqueID>            <ISSNLinking>1932-6203</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015234">HLA-A Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.4.23.-</RegistryNumber>                <NameOfSubstance UI="D016333">HIV Protease</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.4.23.-</RegistryNumber>                <NameOfSubstance UI="C514803">p16 protease, Human immunodeficiency virus 1</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016333" MajorTopicYN="N">HIV Protease</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015234" MajorTopicYN="N">HLA-A Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2013</Year>                <Month>03</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2013</Year>                <Month>07</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2013</Year>                <Month>9</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2013</Year>                <Month>9</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2014</Year>                <Month>5</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">24015196</ArticleId>            <ArticleId IdType="doi">10.1371/journal.pone.0071888</ArticleId>            <ArticleId IdType="pii">PONE-D-13-12010</ArticleId>            <ArticleId IdType="pmc">PMC3756051</ArticleId>        </ArticleIdList>        <ReferenceList>            <Reference>                <Citation>Science. 1993 May 28;260(5112):1273-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8493571</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 1988 Nov 25;242(4882):1171-3</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2460925</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 1994 Dec 15;153(12):5586-92</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">7527444</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8166-70</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">7545295</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Annu Rev Immunol. 1996;14:369-96</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8717519</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunogenetics. 2005 Apr;57(1-2):33-41</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15744535</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Cell Mol Life Sci. 2005 May;62(9):1025-37</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15868101</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2005 Jun;79(12):7728-37</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15919925</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Immunol. 2006 Feb;7(2):173-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16369537</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nat Immunol. 2006 Feb;7(2):179-89</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16388312</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Drug Discov Today. 2006 Mar;11(5-6):203-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16580597</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dis. 2006 Sep 15;194 Suppl 1:S51-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">16921473</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2007 Mar;81(6):2887-98</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17202219</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Bioinformatics. 2007 Apr 15;23(8):942-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17384427</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS One. 2007;2(8):e796</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17726526</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2007 Oct;81(20):11543-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">17670829</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Clin Infect Dis. 2008 Feb 15;46(4):507-15</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18199042</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Infect Dis. 2008 Feb 15;197(4):563-71</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18275276</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Immunol. 2008;9:1</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">18211710</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2009 May;5(5):e1000414</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19424423</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS One. 2009;4(8):e6687</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19690614</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Curr Top Med Chem. 2009;9(11):1016-37</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">19747122</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunogenetics. 2010 Jun;62(6):357-68</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">20379710</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):109-17</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21107269</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>PLoS Pathog. 2011 May;7(5):e1002049</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21589903</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Clin Microbiol Infect. 2011 Sep;17(9):1352-5</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">21635664</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>BMC Bioinformatics. 2011;12:446</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22085524</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Top Antivir Med. 2011 Nov;19(4):156-64</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22156218</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Med Microbiol Immunol. 2012 May;201(2):201-11</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">22200907</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Top Antivir Med. 2013 Feb-Mar;21(1):6-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">23596273</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">10694578</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Hum Immunol. 2000 Sep;61(9):925-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11053636</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2001 Sep;75(18):8681-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">11507213</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Immunol Cell Biol. 2002 Jun;80(3):248-54</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12067412</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Trends Pharmacol Sci. 2002 Aug;23(8):381-8</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12377580</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Nucleic Acids Res. 2003 Jan 1;31(1):298-303</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">12520007</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>AIDS. 2003 Dec 5;17(18):2581-91</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">14685052</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 2004 Feb;78(3):1324-32</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">14722287</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Immunol. 2004 Jun 1;172(11):7212-9</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">15153547</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>Science. 1988 Nov 25;242(4882):1168-71</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">2460924</ArticleId>                </ArticleIdList>            </Reference>            <Reference>                <Citation>J Virol. 1994 Sep;68(9):6103-10</Citation>                <ArticleIdList>                    <ArticleId IdType="pubmed">8057491</ArticleId>                </ArticleIdList>            </Reference>        </ReferenceList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">22575339</PMID>        <DateCompleted>            <Year>2012</Year>            <Month>12</Month>            <Day>26</Day>        </DateCompleted>        <DateRevised>            <Year>2012</Year>            <Month>08</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1567-7257</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>12</Volume>                    <Issue>7</Issue>                    <PubDate>                        <Year>2012</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases</Title>                <ISOAbbreviation>Infect Genet Evol</ISOAbbreviation>            </Journal>            <ArticleTitle>Immunogenetic surveillance of HIV/AIDS.</ArticleTitle>            <Pagination>                <MedlinePgn>1481-91</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.meegid.2012.04.011</ELocationID>            <Abstract>                <AbstractText>Evolutionary pressure by viruses is most likely responsible for the extraordinary allelic polymorphism of genes encoding class I human leukocyte antigens (HLA) and killer immunoglobulin-like receptors (KIR). Such genetic diversity has functional implications for the immune response to viruses and generates population-based variations in HLA class I allele frequencies and KIR gene profiles. The HIV-1 virus has relatively recently established itself as a major human pathogen, rapidly diversifying into a variety of phylogenetic subtypes or clades (A-G) and recombinants in different populations. HIV-1 clade C is the most common subtype in circulation accounting for 48% of all infections, followed by HIV-1 clades A and B which are responsible for 13% and 11% of infections in the current pandemic, respectively. Candidate gene studies of large cohorts of predominantly HIV-1 clade B but also clades C and A infected patients, have consistently shown significant associations between certain HLA class I alleles namely HLA-B*57, B*58, B*27, B*51 and relatively low viraemia. However, there is evidence that other associations between HLA-B*15, B*18 or B*53 and levels of HIV-1 viraemia are clade-specific. Recent genome-wide association studies of HIV-1 clade B exposed cohorts have confirmed that HLA-B, which is the most polymorphic locus in the human genome, is the major genetic locus contributing to immune control of viraemia. Moreover, the presence of natural killer cell receptors encoded by KIR-3DL1 and 3DS1 genes together with certain HLA class I alleles carrying the KIR target motif Bw4Ile80, provides an enhanced ability to control HIV-1 viraemia in some individuals. It is likely that rapid co-evolution of HIV-1 immune escape variants together with an adjustment of human immune response gene profiles has occurred in some exposed populations. Taken together, immunogenetic surveillance of HIV-1 exposed cohorts has revealed important correlates of natural immunity, which could provide a rational platform for the design and testing of future vaccines aimed at controlling the current AIDS pandemic.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2012. Published by Elsevier B.V.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Stephens</LastName>                    <ForeName>Henry A F</ForeName>                    <Initials>HA</Initials>                    <AffiliationInfo>                        <Affiliation>UCL Centre for Nephrology and the Anthony Nolan Laboratories, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK. h.stephens@ucl.ac.uk</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2012</Year>                <Month>05</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Infect Genet Evol</MedlineTA>            <NlmUniqueID>101084138</NlmUniqueID>            <ISSNLinking>1567-1348</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D016915">AIDS Vaccines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D016915" MajorTopicYN="N">AIDS Vaccines</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005805" MajorTopicYN="N">Genes, MHC Class I</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055261" MajorTopicYN="N">Immunogenetic Phenomena</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2011</Year>                <Month>12</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2012</Year>                <Month>04</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2012</Year>                <Month>04</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2012</Year>                <Month>5</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2012</Year>                <Month>5</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2012</Year>                <Month>12</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">22575339</ArticleId>            <ArticleId IdType="pii">S1567-1348(12)00143-8</ArticleId>            <ArticleId IdType="doi">10.1016/j.meegid.2012.04.011</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">26471354</PMID>        <DateCompleted>            <Year>2017</Year>            <Month>08</Month>            <Day>01</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>02</Month>            <Day>28</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1468-1293</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>17</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2016</Year>                        <Month>06</Month>                    </PubDate>                </JournalIssue>                <Title>HIV medicine</Title>                <ISOAbbreviation>HIV Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Presentation of available CTL epitopes that induction of cell-mediated immune response against HIV-1 Koran clade B strain using computational technology.</ArticleTitle>            <Pagination>                <MedlinePgn>460-6</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/hiv.12316</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE">Theoretical predicting cytotoxic T lymphocyte (CTL) epitopes are an important tool in vaccine design and CTL therapy for enhancing our understanding of the cellular immune system. We would like to identify available CTL epitopes against HIV-1 Korean clade B. CTL activity was assessed in freshly isolated peripheral blood mononuclear cells from Korean HIV patients in order to assess whether these CTL epitopes induce a cell-mediated immune response (CMI).</AbstractText>                <AbstractText Label="METHODS">NetCTLpan1.1 software, which is the most popular prediction computer software package, and full atom-based simulation (FABS), which is a 3D modelling system for binding activity between epitopes and human leucocyte antigen (HLA) molecules, were used to predict the peptide-spanning Env region binding to HLA-A*24:02, HLA-A*02:01 and HLA-B*15:01, which are frequently found in the Korean population. Granzyme B and interferon-\xce\xb3 ELISPOT assays were used to determine whether identified CTL epitopes induce CMI.</AbstractText>                <AbstractText Label="RESULTS">Three HIV-1 Korean clade B-specific Env CTL epitopes were identified: Gp41-RYL and Gp41-RQG are localized within gp41, and Gp120-LLQ within gp120. In in vitro assays using granzyme B ELISPOT, Gp120-LLQ and Gp41-RQG induced epitope-specific CTL responses in HLA-restricted cells. In ex vivo assay using IFN-\xce\xb3 ELISPOT, cell-mediated immune responses to Gp41-RYL were present in 50% of HLA-matched patients, and responses to Gp120-LLQ and Gp41-RQG were found in 33% of HLA-matched patients.</AbstractText>                <AbstractText Label="CONCLUSION">In this study, we found that a prediction pipeline for CTL epitopes might be based on the most popular computer prediction software and FABS methods. Our results suggest that these CTL epitopes may provide useful tools and information for the development of a therapeutic vaccine against HIV-1 Korean clade B.</AbstractText>                <CopyrightInformation>\xc2\xa9 2015 The Authors. HIV Medicine published by John Wiley &amp; Sons Ltd on behalf of British HIV Association.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>H</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Division of AIDS, Korea National Institute of Health, Cheongju, Chungbuk, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chung</LastName>                    <ForeName>Y-S</ForeName>                    <Initials>YS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of AIDS, Korea National Institute of Health, Cheongju, Chungbuk, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yoon</LastName>                    <ForeName>C-H</ForeName>                    <Initials>CH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of AIDS, Korea National Institute of Health, Cheongju, Chungbuk, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>S H</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Laboratory Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>S S</ForeName>                    <Initials>SS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of AIDS, Korea National Institute of Health, Cheongju, Chungbuk, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kang</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Division of AIDS, Korea National Institute of Health, Cheongju, Chungbuk, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Choi</LastName>                    <ForeName>B-S</ForeName>                    <Initials>BS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of AIDS, Korea National Institute of Health, Cheongju, Chungbuk, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2015</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>HIV Med</MedlineTA>            <NlmUniqueID>100897392</NlmUniqueID>            <ISSNLinking>1464-2662</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015234">HLA-A Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>82115-62-6</RegistryNumber>                <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.4.21.-</RegistryNumber>                <NameOfSubstance UI="D053804">Granzymes</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058501" MajorTopicYN="N">Enzyme-Linked Immunospot Assay</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D053804" MajorTopicYN="N">Granzymes</DescriptorName>                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015234" MajorTopicYN="N">HLA-A Antigens</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D056910" MajorTopicYN="N">Republic of Korea</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">HIV-1 Korean clade B</Keyword>            <Keyword MajorTopicYN="Y">cell-mediated immune response (CMI)</Keyword>            <Keyword MajorTopicYN="Y">env CTL epitope</Keyword>            <Keyword MajorTopicYN="Y">full atom-based simulation (FABS)</Keyword>            <Keyword MajorTopicYN="Y">therapeutic vaccine</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="accepted">                <Year>2015</Year>                <Month>07</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2015</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2015</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2017</Year>                <Month>8</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">26471354</ArticleId>            <ArticleId IdType="doi">10.1111/hiv.12316</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">27693214</PMID>        <DateCompleted>            <Year>2017</Year>            <Month>12</Month>            <Day>07</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>02</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-0542</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>181</Volume>                    <PubDate>                        <Year>2017</Year>                        <Month>01</Month>                    </PubDate>                </JournalIssue>                <Title>Immunology letters</Title>                <ISOAbbreviation>Immunol Lett</ISOAbbreviation>            </Journal>            <ArticleTitle>Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.</ArticleTitle>            <Pagination>                <MedlinePgn>26-30</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0165-2478(16)30187-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imlet.2016.09.013</ELocationID>            <Abstract>                <AbstractText>Cervical cancers almost are infected by human papillmavirus (HPV), encoding E6 and E7 oncoproteins which are regard as ideal targets on the mechanism of this disease and development of vaccines. HLA (human leukocyte antigen) participates in the local immune response to prevent tumor invasion and progression. But due to highly polymorphism of HLA, prediction shows its importance in this study. More effective immunoinformatics was used for predicting epitopes from HPV-16 E6 and E7, including T- and B-cell epitopes. Eight substitutions are detected. Specifically speaking, for HLA-I, HLA-A*33:03 (26), HLA-B*13:01 (14), HLA-C*03:02 (5) for E6 and HLA-A*02:01 (6), HLA-B*40:01 (5), HLA-C*03:04 (4) for E7 are most frequency. Epitope <sub>41-48</sub>EVYDFAFR for HLA-A*33:03 (0.1) for E6 has best binding affinity, as well as HLA*02:01 and HLA-B*40:01 (0.2) for E7. The mutations of D25E and L83V of E6 and N29S of E7 produce new epitopes, and the percentile values change with them. For HLA-II, seventeen epitopes in the reference at percentile value from 0.22 to 4.76, while in variant from 0.22 to 4.96. For the B-cell epitopes, three most potent epitopes for E6 were listed, and N29S lead the growth of score from 0.81 to 0.83. In summary, E6<sub>40-55</sub>REVYDFAFRDLCIVYR and E7<sub>11-22</sub>YMLDLQPETTDL are the important regions, containing the majority of predicted epitopes. E6 72-83 for HLA-A*02:01 and E6 74-84 for HLA-B*15:02 maybe are the new direct for therapeutic vaccine aimed at L83V variants. HLA-DRB1*15:02 is better binder with T cell in our HLA class II. It is a systematic, detail recognition for T- and B-cell epitopes of HPV-16 E6 and E7 from Southwest China, which may be helpful to design vaccines specifically for women in Southwest China and testing methods specifically for this region. The results of our study may contribute to future researches on vaccines improvement, or screening methods for a particular population.</AbstractText>                <CopyrightInformation>Copyright \xc2\xa9 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chenzhang</LastName>                    <ForeName>Yuwei</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, Institute of Medical Genetics, College of Life Science, Sichuan University, China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and Chongqing, Sichuan and Chongqing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wen</LastName>                    <ForeName>Qiang</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, Institute of Medical Genetics, College of Life Science, Sichuan University, China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and Chongqing, Sichuan and Chongqing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ding</LastName>                    <ForeName>Xianping</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, Institute of Medical Genetics, College of Life Science, Sichuan University, China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and Chongqing, Sichuan and Chongqing, China. Electronic address: brainding@scu.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cao</LastName>                    <ForeName>Man</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, Institute of Medical Genetics, College of Life Science, Sichuan University, China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and Chongqing, Sichuan and Chongqing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Zuyi</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, Institute of Medical Genetics, College of Life Science, Sichuan University, China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and Chongqing, Sichuan and Chongqing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mu</LastName>                    <ForeName>Xuemei</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, Institute of Medical Genetics, College of Life Science, Sichuan University, China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and Chongqing, Sichuan and Chongqing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Tao</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, Institute of Medical Genetics, College of Life Science, Sichuan University, China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and Chongqing, Sichuan and Chongqing, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Govt</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2016</Year>                <Month>09</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Immunol Lett</MedlineTA>            <NlmUniqueID>7910006</NlmUniqueID>            <ISSNLinking>0165-2478</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C068651">E6 protein, Human papillomavirus type 16</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009856">Oncogene Proteins, Viral</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D050725">Papillomavirus E7 Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C059731">oncogene protein E7, Human papillomavirus type 16</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009856" MajorTopicYN="N">Oncogene Proteins, Viral</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D050725" MajorTopicYN="N">Papillomavirus E7 Proteins</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Cervical cancer</Keyword>            <Keyword MajorTopicYN="Y">Human leukocyte antigen</Keyword>            <Keyword MajorTopicYN="Y">Human papillomavirus-16 E6/E7</Keyword>            <Keyword MajorTopicYN="Y">Southwest China</Keyword>            <Keyword MajorTopicYN="Y">T- and B-cell epitopes prediction</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2016</Year>                <Month>07</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2016</Year>                <Month>09</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2016</Year>                <Month>09</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2016</Year>                <Month>10</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2017</Year>                <Month>12</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2016</Year>                <Month>10</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">27693214</ArticleId>            <ArticleId IdType="pii">S0165-2478(16)30187-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.imlet.2016.09.013</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>